

# Best Available Copy

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
15 November 2001 (15.11.2001)

PCT

(10) International Publication Number  
**WO 01/85926 A2**

(51) International Patent Classification<sup>7</sup>: **C12N 15/00**

(21) International Application Number: **PCT/NZ01/00073**

(22) International Filing Date: **4 May 2001 (04.05.2001)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:  
**500844** **5 May 2000 (05.05.2000)** **NZ**

(71) Applicant (*for all designated States except US*): **AGRE-SEARCH LIMITED** [NZ/NZ]; East Street, Ruakura Campus, Hamilton (NZ).

(71) Applicant and

(72) Inventor: **RITVOS, Olli, Visa-Pekka** [FI/FI];  
Visakoivuntie 10 G 13, FIN-02130 Espoo (FI).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **DAVIS, George, Henry** [NZ/NZ]; Invermay Agricultural Centre, Private Bag 50034, Mosgiel, Dunedin (NZ). **GALLOWAY, Susan, May** [NZ/NZ]; AgResearch Molecular Biology Unit, Department of Biochemistry, University of Otago, P.O. Box 56, Dunedin (NZ). **MCNATTY, Kenneth, Patrick** [NZ/NZ]; Wallaceville Animal Research Centre, P.O. Box 40063, Upper Hutt (NZ).

(74) Agents: **WILSON, Kathryn, S. et al.**; Level 12, KPMG Centre, 85 Alexandra Street, Private Bag 3140, Hamilton (NZ).

(81) Designated States (*national*): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.**

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

## Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations* AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG)

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations* AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG)

## Published:

— *without international search report and to be republished upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: **NUCLEOTIDE SEQUENCES INVOLVED IN INCREASING OR DECREASING MAMMALIAN OVULATION RATE**

(57) Abstract: The present invention relates to nucleotide sequences which are involved in increasing or decreasing mammalian ovulation rate. In particular, the invention broadly concerns novel mutations in a gene which is involved in increasing the ovulation rate in heterozygous female mammals; these mutations cause sterility in homozygous female mammals. Knowledge of the mutated gene sequence can be applied to a test for identifying heterozygous of homozygous female and male mammals carrying the mutated gene. This knowledge of the biological function of the gene and its mutations can also be utilised to increase or decrease the ovulation rate of female mammals, or to induce sterility or reduced fertility in female mammals.

WO 01/85926 A2

## 5    **NUCLEOTIDE SEQUENCES INVOLVED IN INCREASING OR DECREASING MAMMALIAN OVULATION RATE**

The present invention relates to nucleotide sequences which are involved in increasing or decreasing mammalian ovulation rate.

10    In particular, the invention broadly concerns novel mutations in a gene which is involved in increasing the ovulation rate in heterozygous female mammals; these mutations cause sterility in homozygous female mammals. Knowledge of the mutated gene sequence can be applied to a test for identifying heterozygous or homozygous female and male mammals carrying the mutated gene. This knowledge of the biological function of the gene and its mutations can also be utilised to increase or decrease the ovulation rate of  
15    female mammals, or to induce sterility or reduced fertility in female mammals.

## **BACKGROUND OF THE INVENTION**

All references, including any patents or patent applications, cited in this specification are hereby incorporated by reference. No admission is made that any reference constitutes prior art. The discussion of the references states what their authors assert, and the  
20    applicants reserve the right to challenge the accuracy and pertinency of the cited documents. It will be clearly understood that, although a number of prior art publications are referred to herein, this reference does not constitute an admission that any of these documents form part of the common general knowledge in the art, in New Zealand or in any other country.

25    The Inverdale high fecundity gene ( $FecX^I$ ) is a major gene for prolificacy in sheep, which was first identified in a Romney flock (Inverdale) consisting of descendants of Romney ewe (A281) all of which had consistently high litter sizes. Segregation studies showed that the gene is carried on the X-chromosome (Davis *et al.*, 1991). A single copy of the gene in heterozygous I+ ewes increases ovulation rate by about one extra egg, and  
30    litter size by about 0.6 lambs per ewe lambing. However, homozygous II ewes carrying

5 two copies of the gene have small, non-functional ovaries, and are infertile (Davis *et al.*, 1992). Studies on foetal I+ and II sheep demonstrated that ovarian development is normal until approximately day 100 of foetal life: germ cell development, ovarian follicular formation and the earliest stages of follicular growth are normal. However, in II foetuses, after day 100 of foetal life follicular development beyond the primary  
10 stage of growth is impaired, and normal secondary follicles are not observed (Smith *et al.*, 1997). As oocytes in II animals increase in diameter ( $>40\ \mu\text{m}$ ) there is no evidence of granulosa cell proliferation, in contrast to what would normally be observed (Braw-Tal *et al.*, 1993; McNatty *et al.*, 1995a; Smith *et al.*, 1997). Thus the presence of infantile, non-functional ovaries in foetal, neonatal and adult II animals is due to a block  
15 in follicular development beyond the primary stage of growth.

A second prolific Romney flock (Hanna, 1995), with no known connection to the Inverdale flock, was also shown to carry an X-linked mutation with a similar phenotype to Inverdale. Confirmation that the Hanna animals carried a mutation ( $\text{FecX}^{\text{H}}$ ) in the Inverdale gene was obtained when homozygous infertile females were produced by  
20 mating Inverdale carrier rams with carrier Hanna ewes (Davis *et al.*, 1995). This Hanna line was maintained at Invermay as a distinct group alongside the original Inverdale line.

As part of the search for the gene responsible for the Inverdale trait, the inventors have constructed a genetic linkage map of the sheep X-chromosome (Galloway *et al.*, 1996), and localised the Inverdale gene to a 10 cM region flanked by microsatellite markers  
25 (Galloway *et al.*, 1999). Localisation of the gene to the sheep X-chromosome narrows the search for candidates to those genes which map to other mammalian X-chromosomes, because, almost without exception, genes on the X-chromosome of one mammal are also present on the X-chromosomes of other mammalian species (Ohno, 1973).

5 Inheritance of the Inverdale gene on the X-chromosome provides a convenient means of producing prolific single copy Inverdale carrier ewes, because all daughters of an Inverdale carrier ram will inherit the gene. The breeder of the rams uses a genetic marker test to identify carrier rams for sale, and commercial breeders purchase these rams to generate prolific ewes, which are subsequently mated to a terminal sire to produce  
10 progeny for slaughter. Commercial use of the Inverdale gene has been shown to be highly beneficial in an existing terminal sire mating system, with an added value over a normal ram of \$1760 per Inverdale ram purchased (Amer *et al.*, 1998). Production of elite rams carrying the gene requires the ability to distinguish between non-carriers (++ females or +Y males) and single copy carriers (I+ females or IY males).

15 A genetic marker test was developed on the basis of inheritance of flanking microsatellite markers around the gene (i.e. a haplotype test) (Galloway *et al.*, 1999); this is illustrated in Figure 1. However, the current test can only identify those animals which have inherited the Inverdale haplotype from a known carrier, and is not 100% accurate, because it does not detect the Inverdale gene itself. The haplotype from the  
20 same region of the X-chromosome in sheep of the Hanna pedigree, which carry the unrelated version of Inverdale, was different from the haplotype seen in descendants of A281.

In 1996 growth differentiation factor 9 (GDF-9), a member of the transforming growth factor beta (TGF- $\beta$ ) superfamily, was shown to be specifically expressed in the oocyte  
25 of adult mice, where it is required for folliculogenesis (Dong *et al.*, 1996). GDF-9 messenger RNA is synthesised only in the oocyte, from the primordial/primary one-layer follicular stage until after ovulation, and female GDF-9 knockout mice are infertile due to a block in follicular development at this primary one-layer follicle stage. Animals homozygous for the Inverdale gene are infertile, with a similar phenotype to the GDF-9  
30 knockout mouse (McNatty *et al.*, 1995b). GDF-9 was subsequently mapped to sheep chromosome 5, and therefore could not be responsible for the Inverdale phenotype (Sadighi *et al.*, 1998).

5 A second related member of this family, GDF-9B, also called BMP15, was identified in mouse and human ovaries, and found to be co-expressed with GDF-9 (Laitinen *et al.*, 1998, Dube *et al.*, 1998). BMP15 was mapped to the X-chromosome in mice, close to Fsc1 (Dube *et al.*, 1998). Fsc1 (fibrous sheath component) is also known as Akap4 (A kinase anchor protein 4), which has been mapped to the mouse X-chromosome at 1.6  
10 cM from the centromere (Mouse Genome Database (MGD); October 1999) and to band p11.2 of the human X-chromosome (Dube *et al.*, 1998). Preliminary studies in Inverdale sheep (++, I+ and II genotypes), using a molecular probe that does not distinguish between the genotypes, show that GDF-9B mRNA is expressed in oocytes of primary but not primordial follicles, and that expression of this mRNA within the ovary is  
15 exclusive to oocytes (Galloway *et al* 2000).

Members of the TGF- $\beta$  superfamily have similar gene structures. The GDF-9B coding region is contained within two exons separated by an intron of 4.2 kb (human) and 3.5 kb (mouse) (Dube *et al.*, 1998). In humans the full-length 1176 bp coding sequence produces a 392 amino acid prepropeptide, the first 17 amino acids of which correspond  
20 to a secretory signal. The full-length prepropeptide in human and mouse includes the processing site for proteolytic cleavage to release a 125 amino acid mature active C-terminal peptide and an N-terminal propeptide product (Laitinen *et al.*, 1998, Dube *et al.*, 1998). The intron sequence lies within the propeptide domain, so that the entire mature coding region is found within exon 2.

25 The sequence of the human BMP15 (GDF-9B) wild type gene is disclosed in US 5,728,679 and US 5,635,372. The wild type protein is disclosed as being useful in the treatment of bone and cartilage and/or other connective tissue defects, and in wound healing and tissue repair.

The inventors have now identified a mutated form of the sheep GDF-9B gene in sheep  
30 expressing the Inverdale or Hanna phenotype, and discovered for the first time that this

- 5 mutated form of GDF-9B is responsible for the enhanced ovulation seen in these sheep and for the sterility seen in homozygous sheep.

The present invention is broadly directed to the mutated sequence and its corresponding encoded protein.

### SUMMARY OF THE INVENTION

- 10 Accordingly, in one aspect, the present invention provides an isolated mutated GDF-9B nucleic acid molecule, comprising a nucleotide sequence selected from the group consisting of:

- a) SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, or SEQ ID NO: 7;
- b) a sequence able to hybridise under stringent conditions to the molecule(s)  
15 in (a);
- c) a sequence which is a functional variant or fragment of the molecule(s) defined in (a);
- d) a sequence complementary to the molecule(s) defined in (a), (b) or (c); and
- e) an anti-sense sequence corresponding to any of the molecule(s) in (a) – (d).

- 20 The nucleic acid molecule may be an RNA, cRNA, genomic DNA or cDNA molecule, and may be single- or double-stranded. The nucleic acid molecule may also optionally comprise one or more synthetic, non-natural or altered nucleotide bases, or combinations thereof.

- The present invention further provides a method of identifying a mammal which carries  
25 a mutated GDF-9B nucleic acid molecule, said method comprising the steps of:

- (i) obtaining a tissue or blood sample from the mammal;
- (ii) isolating DNA from the sample;



- 5           (iii) optionally isolating GDF-9B DNA from the DNA obtained at step (i);
- (iv) optionally probing the DNA with a probe complementary to the mutated GDF-9B DNA of the invention;
- (v) optionally amplifying the amount of mutated GDF-9B DNA; and
- (vi) determining whether the GDF-9B sequence DNA obtained in Step (ii)
- 10           carries a mutation associated with sterility, or with increased or decreased ovulation.

Preferably the amplification step (v) may be performed by any convenient method, such as the polymerase chain reaction, or ligase chain reaction.

According to still a further aspect the present invention provides a genetic marker for

15   DNA- assisted selection for enhanced ovulation or sterility in a mammal, comprising a nucleic acid molecule which specifically hybridises to a nucleotide sequence according to the first aspect of the invention, or to genomic DNA comprising or associated with the mutated GDF-9B nucleic acid molecule.

The mammal may be male or female, and may be a human, or a domestic, companion,

20   zoo or feral mammal. Preferably the mammal is selected from humans, sheep, cattle, goats, deer, horses, camelids, possums, pigs, mice, rats, weasels, rabbits, hares, ferrets, cats and dogs.

In a further aspect, the present invention provides an isolated polypeptide encoded by a nucleic acid molecule having a sequence set out in one of (a)-(d) above. Preferably the

25   polypeptide has an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, and SEQ ID NO: 8, or a functional variant or fragment thereof.

In yet a further aspect, the invention provides an isolated polypeptide having an amino acid sequence comprising SEQ ID NO: 10, or a functional variant or fragment thereof.

5 In an additional aspect, the invention provides an isolated nucleic acid molecule having a nucleotide sequence comprising SEQ ID NO: 9, or a functional fragment or variant thereof.

In a still further aspect, the invention provides an isolated nucleic acid molecule which encodes a polypeptide substantially as described above.

10 In a further aspect, the invention provides a method of modulating the ovulation rate of a female mammal, said method comprising the step of administering to said mammal an effective amount of a mutated GDF-9B polypeptide, the wild type GDF-9B polypeptide, or a functional fragment or variant of either.

The invention also provides a method of increasing the ovulation rate of a female  
15 mammal which does not carry a mutated GDF-9B nucleic acid molecule, comprising the step of administering to said mammal an effective amount of a mutated GDF- 9B polypeptide or a functional variant or fragment thereof.

Furthermore, the invention also provides a method of increasing the ovulation rate of a sterile female mammal which carries two copies of the mutated GDF-9B nucleic acid  
20 molecule, comprising the step of administering to said mammal an effective amount of a wild type GDF-9B polypeptide.

In another aspect, the invention provides a method of increasing or reducing the ovulation rate, or of inducing sterility in a female mammal, comprising the step of administering an effective amount of an agent selected from the group consisting of:

- 25
- a) an immunising-effective amount of a wild type or mutated GDF-9B polypeptide, or a functional fragment or variant thereof;
  - b) an anti-sense nucleic acid molecule directed against DNA encoding a wild type or mutated GDF-9B polypeptide or a functional fragment or variant thereof;



- 5           c)     a ligand which binds to, or an antigen of, the wild type or mutated GDF-9B polypeptide or a functional fragment or variant thereof;

thereby to inhibit the biological activity of the mutated or wild type GDF-9B polypeptide.

In yet a further aspect, the invention provides a composition comprising an effective  
10     amount of a mutated GDF-9B polypeptide or a functional fragment or variant thereof, together with a pharmaceutically or veterinarily acceptable carrier or diluent.

In still a further aspect, the invention provides a composition comprising an effective amount of an agent selected from the group consisting of:

- a)     a mutated GDF-9B polypeptide according to the invention;
- 15         b)     a wild type GDF-9B polypeptide according to the invention;
- c)     an anti-sense nucleic acid molecule directed against the wild type or mutated GDF-9B polypeptide of the invention;
- d)     a ligand which binds to, or an antigen of, the wild type or mutated GDF-9B polypeptide of the invention;

20     together with a pharmaceutically or veterinarily acceptable carrier or diluent.

According to yet a further aspect, the invention provides a construct or vector comprising a nucleic acid molecule substantially as described above.

The present invention also provides a host cell transformed with a vector or construct comprising a nucleic acid molecule of the invention.

25     According to a further aspect, the invention provides an isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 12 or SEQ ID NO: 14, or a functionally active fragment or variant thereof.

5 The invention also provides an isolated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 13 and SEQ ID NO: 15.

In yet another aspect of the invention provides an isolated, functionally active variant polypeptide as set forth in SEQ ID NO: 11.

According to a still further aspect of the present invention there is provided an isolated  
10 nucleic acid molecule comprising nucleic acid sequence as set forth in SEQ ID NO: 16.

The present invention also provides an isolated polypeptide comprising an amino acid sequence as set forth in SEQ ID NO: 17.

The invention also encompasses a method for reducing the ovulation rate or inducing sterility in a possum comprising the step of administering an effective amount of a  
15 polypeptide having an amino acid sequence as set forth in SEQ ID NO: 17 or a functional variant or fragment thereof.

While the invention is broadly as defined above, it will be appreciated by those persons skilled in the art that it is not limited thereto, and that it also includes embodiments of which the following description gives examples.

## 20 BRIEF DESCRIPTION OF DRAWINGS

In particular, preferred aspects of the invention will be described in relation to the accompanying drawings, in which:

Figure 1 shows a genetic linkage map of the ovine X-chromosome. Genetic distances are in Kosambi centiMorgans (cM). The Inverdale gene maps into the region indicated  
25 by a hatched bar.

Figure 2a shows the nucleotide sequence of exon 2 of GDF-9B in Inverdale sheep. The position of the Inverdale T to A nucleotide substitution (92 nucleotides beyond the processing site) is marked in bold. The triplet codon affected by this substitution is

5 underlined. The processing site for proteolytic cleavage of propeptide from the mature fragment and the TGA stop codon are boxed. The mature peptide coding sequence is between the two boxes.

Figure 2b shows the nucleotide sequence of exon 2 of GDF-9B in Hanna sheep. The position of the Hanna C to T nucleotide substitution (67 nucleotides beyond the  
10 processing site) is marked in bold. The triplet codon affected by this substitution is underlined. The processing site for proteolytic cleavage of propeptide from mature fragment and the TGA stop codon are boxed. The mature peptide coding sequence is between the two boxes.

Figure 2c shows the nucleotide sequence of bp 394-599 of Figure 2a.

15 Figure 2d shows the nucleotide sequence of bp 394-599 of Figure 2b.

Figure 2e shows the nucleotide sequence of bp 472-486 of Figure 2a.

Figure 2f shows the nucleotide sequence of bp 448-462 of Figure 2b.

Figure 3a shows the deduced amino acid sequence of the GDF-9B Inverdale protein encoded by the nucleotide sequence of Figure 2a. The mature GDF-9B is shown in  
20 normal type and the portion of the propeptide is in italics. The amino acid (Aspartic acid, D) produced by the Inverdale base substitution is marked in bold.

Figure 3b shows the deduced amino acid sequence of the truncated GDF-9B Hanna protein encoded by the nucleotide sequence of Figure 2b. The mature GDF-9B peptide is shown in normal type and the portion of the propeptide is in italics. The wild type  
25 amino acid (Glutamine, Q) becomes a stop codon (END) in the Hanna mutant.

Figure 4 shows a comparison of predicted amino acid sequence of sheep GDF-9B with human and mouse. Numbers in brackets above the line indicate amino acid positions of the mature peptide. The open triangle shows the position of the Leu polymorphism, and the black triangle indicates the position of the single intron. The RRAR putative

5 processing site and the conserved cysteins are shaded grey. Positions of the  $FecX^I$  and  $FecX^H$  mutations at amino acids 23 and 31 are in bold.

Figure 5 shows a chromatogram of GDF-9B sequence from Inverdale, Hanna and wildtype sheep-showing region where mutations occur.

Figure 6 shows the alignment of mutated region of predicted  $FecXI$  protein with TGF $\beta$   
10 superfamily members from other species.

Figure 7 shows a linkage map of the region of sheep X chromosome containing the GDF9-B gene.

Figure 8 shows the results of a SNP variant detection assay of sheep carrying Inverdale  $FecX^I$  mutation, and non-carriers, using *XbaI* digestion of a forced PCR frag) non-  
15 carrier, an( I+) heterozygote and an(II) homozygote carrier are shown beside heterozygote females (samples A1, A2), carrier rams (samples A5, A10) and non-carrier rams (samples A3, A4, A6, A7, A8, A11, A12 and A13).

## DETAILED DESCRIPTION OF THE INVENTION

The mutations in the GDF-9B gene found in Inverdale and Hanna sheep have been  
20 shown for the first time to be responsible for the increased ovulation rates seen in heterozygous animals and for sterility seen in homozygous animals.

For the purposes of the specification it will be clearly understood that the word “comprising” means “including but not limited to,” and that the word “comprises” has a corresponding meaning.

25 The term “isolated” means substantially separated or purified away from contaminating sequences in the cell or organism in which the nucleic acid naturally occurs, and includes nucleic acids purified by standard purification techniques as well as nucleic acids prepared by recombinant technology, including PCR technology, and nucleic acids

5 which have been synthesised. Preferably, the nucleic acid molecule is isolated from the genomic DNA of sheep expressing the Inverdale or Hanna phenotype.

The term "modulation of ovulation" means increasing or decreasing the rate of ovulation compared to the rate observed in an untreated mammal.

The term "ligand" refers to any molecule which can bind to another molecule such as  
10 a polypeptide or peptide, and should be taken to include, but not be limited to, antibodies and phage display molecules.

The probe and primers used in this method also form a part of this invention. Said probes and primers may comprise a fragment of the nucleic acid molecule of the invention capable of hybridising under stringent conditions to a mutated GDF-9B gene  
15 sequence. Such probes and primers are also useful, in studying the structure and function of the mutated gene and for obtaining homologs of the gene from mammals other than sheep expressing the Inverdale or Hanna phenotype.

Nucleic acid probes and primers can be prepared based on nucleic acids according to the present invention. A "probe" comprises an isolated nucleic acid attached to a detectable  
20 label or reporter molecule. Typical labels include radioactive isotopes, ligands, chemiluminescent or fluorescent agents, and enzymes.

A "fragment" of a nucleic acid is a portion of the nucleic acid that is less than full length, and comprises at least a minimum sequence capable of hybridising specifically with a nucleic acid molecule according to the invention, or a sequence complementary thereto,  
25 under stringent conditions as defined below. A "fragment" of a polypeptide is a portion of the polypeptide which is less than full length, but which still retains the biological function of either increasing or decreasing the ovulation rate of a mammal, or causing sterility in a mammal. Hence, a fragment according to the invention has at least one of the biological activities of the nucleic acid or polypeptide of the invention.

5     “Primers” are short nucleic acids, preferably DNA oligonucleotides 15 nucleotides or more in length, which are annealed to a complementary target DNA strand by nucleic acid hybridisation to form a hybrid between the primer and the target DNA strand, then extended along the target DNA strand by a polymerase, preferably a DNA polymerase. Primer pairs can be used for amplification of a nucleic acid sequence, e.g. by the  
10    polymerase chain reaction (PCR) or other nucleic acid amplification methods well known in the art. PCR-primer pairs can be derived from the sequence of a nucleic acid according to the present invention, for example, by using computer programs intended for that purpose such as Primer (Version 0.5<sup>®</sup> 1991, Whitehead Institute for Biomedical Research, Cambridge, MA).

15    Methods for preparing and using probes and primers are described, for example, in Sambrook et al. *Molecular Cloning: A Laboratory Manual*, 2nd ed, vol. 1-3, ed Sambrook et al. Cold Spring Harbour Laboratory Press, Cold Spring Harbour, NY, 1989.

Probes or primers can be free in solution or covalently or noncovalently attached to a solid support by standard means.

20    “Stringent conditions” for the amplification of a target nucleic acid sequence (eg by PCR) using a particular amplification primer pair, are conditions that permit the primer pair to hybridise only to the target nucleic acid sequence to which a primer having the corresponding wild type sequence (or its complement) would bind.

25    Nucleic acid hybridisation is affected by such conditions as salt concentration, temperature, or organic solvents, in addition to the base composition, length of the complementary strands, and the number of nucleotide base mismatches between the hybridising nucleic acids, as will be readily appreciated by those skilled in the art.

When referring to a probe or primer, the term “specific for (a target sequence)” indicates that the probe or primer hybridises under stringent conditions only to the target sequence  
30    in a given sample comprising the target sequence.



5 In one embodiment, the invention provides a genetic marker for DNA-assisted selection of animals for increased ovulation or sterility in sheep, goats, cattle, deer, mice, rats or any other commercially important mammal. The invention provides a means of using a nucleic acid molecule containing sequence derived from the mutated GDF-9B DNA sequence, or genomic DNA that is associated with the mutated GDF-9B gene, to identify  
10 sequence variants in individual animals that are associated with increased ovulation or sterility of that animal. Although these variants may not necessarily give rise to the increased ovulation or sterility trait directly, they will be closely enough associated with it to predict the trait. The methods by which these sequence variants are identified are known in the art, and include, but are not limited to, restriction fragment length  
15 polymorphism (RFLP), AFLP, direct sequencing of DNA within or associated with the mutated GDF-9B gene, or identification and characterisation of variable number of tandem repeats (VNTR), or microsatellite polymorphisms (di-or tri-nucleotide repeats), detection and characterisation of single nucleotide polymorphisms (SNP's).

The polypeptide may be produced by expression of a suitable vector comprising the  
20 nucleic acid molecule of the invention or a functional variant or fragment thereof, in a suitable host cell as would be understood by a person skilled in the art.

The cloning vector may be selected according to the host or host cell to be used. Useful vectors will generally have the following characteristics:

- (a) the ability to self-replicate;
- 25 (b) the possession of a single target for any particular restriction endonuclease; and
- (c) desirably, carry genes for a readily selectable marker such as antibiotic resistance.

Two major types of vector possessing these characteristics are plasmids and bacterial viruses (bacteriophages or phages). Presently preferred vectors may include the following: the pUC, pBlueScript, pGEM, PGEX, pBK-CMV, lambda ZAP, lambda  
30 GEM and pSP series. However, this list should not be seen as limiting the scope of the

5 present invention.

The DNA molecules of the invention may be expressed by placing them in operable linkage with suitable control sequences in a replicable expression vector. Control sequences may include origins of replication, a promoter, enhancer and transcriptional terminator sequences amongst others. The selection of the control sequence to be included in the expression vector is dependent on the type of host or host cell intended to be used for expressing the DNA.

Generally, procaryotic, yeast or mammalian cells are useful hosts. Also included within the term hosts are plasmid vectors. Suitable procaryotic hosts include E. coli, Bacillus species and various species of Pseudomonas. Commonly used promoters such as  $\beta$ -lactamase (penicillinase) and lactose (lac) promoter systems are all well known in the art. Any available promoter system compatible with the host of choice can be used. Vectors used in yeast are also available and well known. A suitable example is the 2 micron origin of replication plasmid.

Similarly, vectors for use in mammalian cells are also well known. Such vectors include well known derivatives of SV-40, adenovirus, retrovirus-derived DNA sequences, Herpes simplex viruses, and vectors derived from a combination of plasmid and phage DNA.

Further eucaryotic expression vectors are known in the art (e.g. P.J. Southern and P.Berg, *J. Mol. Appl. Genet.* 1 327-341 (1982); S. Subramani et al., *Mol.Cell.Biol.* 1, 854-864 (1981); R J. Kaufmann and P.A. Sharp, "Amplification and Expression of Sequences Cotransfected with a Modular Dihydrofolate Reducase Complementary DNA Gene, *J. Mol. Biol.* 159, 601-621 (1982); R J. Kaufmann and P.A. Sharp, *Mol.Cell.Biol.* 159, 601-664(1982); S.I. Scahill et al., "Expressions And Characterisation Of The Product Of A Human Immune Interferon DNA Gene In Chinese Hamster Ovary Cells," *Proc. Natl. Acad. Sci. USA.* 80, 4654-4659 (1983); G. Urlaub and L.A. Chasin, *Proc. Natl. Acad. Sci. USA.* 77, 4216-4220, (1980).

5 The expression vectors useful in the present invention contain at least one expression control sequence that is operatively linked to the DNA sequence or fragment to be expressed. The control sequence is inserted in the vector in order to control and to regulate the expression of the cloned DNA sequence. Examples of useful expression control sequences are the lac system, the trp system, the tac system, the trc system, major  
10 operator and promoter regions of phage lambda, the glycolytic promoters of yeast acid phosphatase, e.g. Pho5, the promoters of the yeast alpha-mating factors, and promoters derived from polyoma, adenovirus, retrovirus, and simian virus, e.g. the early and late promoters of SV40, and other sequences known to control the expression of genes of prokaryotic and eucaryotic cells and their viruses or combinations thereof.

15 In the construction of a vector it is also an advantage to be able to distinguish the vector incorporating the foreign DNA from unmodified vectors by a convenient and rapid assay. Reporter systems useful in such assays include reporter genes, and other detectable labels which produce measurable colour changes, antibiotic resistance and the like. In one preferred vector, the  $\beta$ -galactosidase reporter gene is used, which gene is  
20 detectable by clones exhibiting a blue phenotype on X-gal plates. This facilitates selection. In one embodiment, the  $\beta$ -galactosidase gene may be replaced by a polyhedrin-encoding gene; which gene is detectable by clones exhibiting a white phenotype when stained with X-gal. This blue-white color selection can serve as a useful marker for detecting recombinant vectors.

25 Once selected, the vectors may be isolated from the culture using routine procedures such as freeze-thaw extraction followed by purification.

For expression, vectors containing the DNA of the invention and control signals are inserted or transformed into a host or host cell. Some useful expression host cells include well-known prokaryotic and eucaryotic cells. Some suitable prokaryotic hosts  
30 include, for example, E.coli, such as E. coli, S G-936, E. coli HB 101, E. coli W3110, E.coli X1776, E. coli, X2282, E. coli, DHT, and E. coli, MR01, Pseudomonas, Bacillus,

5 such as Bacillus subtilis, and Streptomyces. Suitable eucaryotic cells include yeast and other fungi, insect, animal cells, such as COS cells and CHO cells, human cells in tissue culture.

Depending on the host used, transformation is performed according to standard techniques appropriate to such cells. For prokaryotes or other cells that contain  
10 substantial cell walls, the calcium treatment process (Cohen, S N *Proceedings, National Academy of Science, USA* 69 2110 (1972)) may be employed. For mammalian cells without such cell walls the calcium phosphate precipitation method of Graeme and Van Der Eb, *Virology* 52:546 (1978) is preferred. Transformations in yeast according to the method of Van Solingen et al. *J.Bact.* 130: 946 (1977) and Hsiao et al. *Proceedings, National Academy of Science*, 76: 3829 (1979).  
15

Upon transformation of the selected host with an appropriate vector the polypeptide or peptide encoded can be produced, often in the form of fusion protein, by culturing the host cells. The polypeptide or peptide of the invention may be detected by rapid assays as indicated above. The polypeptide or peptide is then recovered and purified as  
20 necessary. Recovery and purification can be achieved using any of those procedures known in the art, for example by absorption onto and elution from an anion exchange resin. This method of producing a polypeptide or peptide of the invention constitutes a further aspect of the present invention.

Host cells transformed with the vectors of the invention also form a further aspect of the  
25 invention.

In addition, nucleotides and peptides having substantial identity to the nucleotide and amino acid sequences of the invention can also be employed in preferred embodiments. Here "substantial identity" means that two sequences, when optimally aligned such as by the programs GAP or BESTFIT (nucleotides and peptides) using default gap weights,  
30 or as measured by computer algorithm BLASTP (peptides) or BLAST X (nucleotides), share at least 60%, preferably 75%, and most preferably 90-95% sequence identity.

5 Preferably residue positions which are not identical differ by conservative amino acid substitutions. For example, the substitution of amino acids having similar chemical properties such as charge or polarity are not likely to effect the properties of a protein. Examples include glutamine for asparagine or glutamic acid for aspartic acid.

The term "variant" as used herein includes nucleic acid molecules and polypeptides and  
10 peptides having "substantial identity" to the sequences of the invention. The variant may result from modification of the native nucleotide or amino acid sequence by such modifications as insertion, substitution or deletion of one or more nucleotides or amino acids or it may be a naturally-occurring variant. The term "variant" also includes homologous sequences which hybridise to the sequences of the invention under standard  
15 hybridisation conditions defined as 2 x SSC at 65°C, or preferably under stringent hybridisation conditions defined as 6 x SCC at 55°C, provided that the variant is capable of modulating the ovulation rate of a female mammal. Where such a variant is desired, the nucleotide sequence of the native DNA is altered appropriately. This alteration can be effected by synthesis of the DNA or by modification of the native DNA, for example,  
20 by site-specific or cassette mutagenesis. Preferably, where portions of cDNA or genomic DNA require sequence modifications, site-specific primer directed mutagenesis is employed, using techniques standard in the art.

The term "protein or polypeptide" refers to a protein encoded by the nucleic acid molecule of the invention, including fragments, mutations and homologues having the  
25 same biological activity i.e. ovulation modulating activity. The protein or polypeptide of the invention can be isolated from a natural source, produced by the expression of a recombinant nucleic acid molecule, or chemically synthesised.

In a further aspect, the invention provides the use of the mutated GDF-9B polypeptide, which has the amino acid sequence set out in figure 3a or 3b, or a variant or fragment  
30 thereof having substantial activity thereto, in a method of modulating the ovulation rate of a mammal.

- 5     The method may comprise administering to said mammal an effective amount of mutated or wildtype GDF-9B or antibody or antigen thereto, or a variant thereof.

Preferably, the modulation of the ovulation rate comprises inducing sterility in the female mammal by the administration of a ligand for, or antigen of, mutated GDF-9B to reduce the level of endogenous mutated GDF-9B.

- 10    An additional aspect of the present invention provides a ligand which binds to a polypeptide of the invention. Most usually, the ligand is an antibody. It should be appreciated that the term "antibody" encompasses fragments or analogues of antibodies which retain the ability to bind to a polypeptide of the invention, including but not limited to Fv, F(ab)<sub>2</sub> fragments, ScFv molecules and the like. The antibody may be  
15    polyclonal or monoclonal, but is preferably monoclonal. In some embodiments the ligand may be a phage display molecule.

- According to a further aspect, there is provided a composition comprising at least the polypeptide of the invention and a pharmaceutically or veterinarily acceptable carrier or diluent. More than one polypeptide of the invention can of course, be included in the  
20    composition.

According to a still further aspect of the present invention there is provided a kit for identifying male and female mammals which carry a single (heterozygous) copy and/or females carrying two (homozygous) copies of a mutated GDF-9B nucleic acid molecule of the invention, comprising:

- 25    •     primer pairs for amplification of the appropriate region of GDF-9B; and optionally one or more of
- buffer salt solution for the amplification, such as PCR amplification;
  - deoxynucleotide mixtures;
  - thermostable DNA polymerase enzyme;



- 5     •     control DNA from the species being tested;
- appropriate standards;
- an appropriate detection system, which could comprise one of the primers in each pair being labelled fluorescently or otherwise, a labelled probe for detection of the product; and
- 10    •     instructions and protocols for the amplification, and subsequent detection of the amplification products and interpretation of results.

The invention also provides a kit for detecting circulating mutated GDF-9B protein in a mammal. Such a kit may comprise a standard ELISA or enzyme immunoassay format kit familiar to those skilled in the art; for example the kit may contain specific antibody  
15   directed to the mutated GDF-9B protein, and standard secondary antibody amplification components to enhance the signal. The antibodies may be conjugated to a fluorescent or radioactive or chemiluminescent label, or the secondary antibody may be labelled. Appropriate solutions, controls, buffers, instructions and protocols may also be supplied.

20   The invention will now be described in detail by way of reference only to the following non-limiting examples and drawings.

### **Animals**

The animals tested in this study were from AgResearch Inverdale breeding flocks located at the Invermay Agricultural Centre and Woodlands Research Station, and from  
25   the commercial flocks of Mr Arnold Gray, Orawia, Southland (Gray and Davis, 1995). All Inverdale carrier animals were descendants of the original Inverdale ewe (A281) in which the Inverdale gene was first detected.

## 5 Phenotypic measurements

Carrier status of ewes was determined by laparoscopy to identify infertile II ewes, or ovulation rate to distinguish I+ carriers from ++ non-carriers.

Carrier status of rams was either assigned on the basis of ovulation rates of their daughters. Following the discovery of infertile ovaries in II ewes, a faster method for progeny testing of rams was employed by mating each ram to seven to ten I+ ewes and carrying out laparoscopy of the daughters at 6 months. Any resulting infertile II offspring confirm the sire as a carrier. The aim was to produce five daughters per ram, as the probability of an IY ram having no daughters with streak ovaries in a sample of five daughters is only 0.031 (Davis *et al.* 1994).

## 15 DNA purification and sequencing

DNA was purified from the white blood cells present in 5 to 10 ml of whole blood from each animal (Montgomery and Sise, 1990). Sequencing of all subclones and PCR products was carried out by the commercial service operated by the University of Otago Centre for Gene Research (ABI 373 automated sequencer).

## 20 DNA markers

Microsatellite (dinucleotide repeat) markers which amplified DNA from sheep were developed within the AgResearch Molecular Biology Unit as previously described (Galloway *et al.*, 1996), or were from the cattle and sheep genetic mapping literature. New markers were mapped on to the sheep X-chromosome as previously described (Galloway *et al.*, 1996).

## PCR amplification and restriction digests of ovine GDF-9B gene products

Standard conditions for Polymerase Chain Reaction (PCR) amplification of genomic DNA were used. Primers were designed from the human and mouse sequences (Galloway *et al.*, 2000), and shown to amplify gene fragments successfully from sheep

5 DNA. PCR products containing the single nucleotide mutations were digested with commercially-available restriction enzymes *SpeI*, *BsrSI* and/or *XbaI* using standard conditions recommended by the manufacturer. PCR products and restriction fragment products were identified by electrophoretic separation in 2 – 3% agarose gels alongside commercially available DNA size markers.

## 10 Sequencing and Mutation Detection Methods

We sequenced the sheep GDF-9B gene in all three genotypes (Inverdale *FecX<sup>I</sup>*, Hanna *FecX<sup>H</sup>* and wildtype *FecX<sup>+</sup>*) from PCR fragments (Galloway *et al.*, 2000), and sequencing was carried out on an ABI 373 sequencer. We confirmed the single base substitutions by sequencing genomic DNA covering the entire coding region from at least six animals carrying each allele (*FecX<sup>I</sup>*, *FecX<sup>H</sup>* and *FecX<sup>+</sup>*). Aside from the *FecX<sup>H</sup>* or *FecX<sup>I</sup>* base substitutions (Figures 2a and 2b) only one other variation was detected in the GDF-9B gene in sheep, namely a single Leu codon (CTT) deletion at L10 or L11 in the signal sequence in some animals (refer Figures 4 and 5). The Leu deletion is not associated with either the *FecX<sup>H</sup>* or *FecX<sup>I</sup>* alleles, and appears breed-related. The *FecX<sup>H</sup>* C→T substitution results in loss of a *BsrSI* restriction site (actg/gn) and gain of a *SpeI* site (a/ctagt). We confirmed this base substitution by demonstrating *SpeI* cleavage of a 541 bp PCR product spanning this region into 476 and 65 bp fragments in *FecX<sup>H</sup>/FecX<sup>H</sup>* females and *FecX<sup>H/Y</sup>* males, but not in *FecX<sup>I</sup>* and wildtype animals. In sheep carrying a copy of each allele (*FecX<sup>I</sup>/FecX<sup>H</sup>*) all three fragments were identified (541, 476 and 65bp). Similarly, *BsrSI* cleaved fragments occurred for *FecX<sup>I</sup>* and wildtype animals but not *FecX<sup>H</sup>* carriers. A 154 bp PCR product from DNA of *FecX<sup>I</sup>* carriers (produced from primers:

#12 (GAAGTAACCAGTGTTCCCTCCACCCTTTCT); and

#13 (CATGATTGGGAGAATTGAGACC));

5 generated a forced *Xba*I restriction site. *Xba*I (t/ctaga) cleaved PCR products generated from *FecX<sup>f</sup>/FecX<sup>f</sup>* females and *FecX<sup>f/y</sup>* males carrying the A allele (tctaga), but not wildtype or *FecX<sup>H</sup>* PCR products carrying the T allele (tctagt). Thus *Xba*I cleaved the 154 bp PCR product to a 124 bp fragment by removing the 30 nucleotide primer #12 only in *FecX<sup>f</sup>* carriers. All restriction digests were carried out on aliquots of PCR  
10 products as specified by the manufacturers and fragments were separated in 3% FMC Metaphor agarose gels.

### Linkage Mapping Methods

We constructed a sheep X-chromosome genetic linkage map by multipoint analysis using CRIMAP as previously described (Galloway *et al.*, 1996) and mapped additional  
15 markers *MAOA*, *McM551*, *OarMP1*, and *TIMP1* (Galloway *et al.*, 2000). *FecX<sup>f</sup>* and *GDF-9B* were mapped in the Inverdale linkage mapping families generated by mating nine carrier males (*FecX<sup>f/y</sup>*) to wildtype females to produce 62 heterozygous *FecX<sup>f</sup>/FecX<sup>+</sup>* female progeny in the second generation. These 62 females produced 96 homozygous *FecX<sup>f</sup>/FecX<sup>f</sup>* or heterozygous *FecX<sup>f</sup>/FecX<sup>+</sup>* female progeny when mated to  
20 10 *FecX<sup>f/y</sup>* males. We determined carrier status of Inverdale animals by laparoscopy to identify *FecX<sup>f</sup>/FecX<sup>f</sup>* infertile females and by progeny testing and laparoscopy of female offspring to identify *FecX<sup>f/y</sup>* males. Parentage was confirmed with genetic markers and all *FecX<sup>f</sup>/FecX<sup>+</sup>* females selected in the third generation were full siblings of *FecX<sup>f</sup>/FecX<sup>f</sup>* infertile females. No DNA was collected from the wildtype females in the  
25 first generation. We mapped *GDF-9B* on the basis of the T→A mutation in the gene coding region.

## RESULTS

### Sequencing results

PCR fragments encoding the entire mature peptide were sequenced from Inverdale and  
30 Hanna genomic DNA. The sequenced region also included most of the propeptide in

5 exon 2 (from 70 bases 3' to the human/mouse intron/exon boundary to 30 bases beyond the tga stop codon ). Sequence from these two sheep lines was compared with the wild-type sheep sequence for GDF-9B. Sequence data revealed two distinct single base substitutions within the mature GDF-9B peptide, one segregating within the Inverdale pedigree and one within the Hanna pedigree (Figure 2).

10 In Hanna animals the C nucleotide at position 67 nucleotides beyond the mature peptide processing site is a T. This converts the codon CAG (coding for the amino acid glutamine (G)) to the codon TAG (coding for termination), and would result in a truncated mature protein (Figure 3b).

In Inverdale animals the T nucleotide at position 92 nucleotides beyond the mature  
15 peptide processing site has become an A, converting the codon GTC (amino acid valine (V)) to GAC (amino acid aspartic acid (D)) (Figure 3a).

#### **Verification of the single base substitutions**

These single base substitutions have been verified by sequencing at least 6 animals carrying each genotype (Inverdale, Hanna and non-carrier wildtype). Each animal was  
20 sequenced at least once (Table 1). In this subset of animals neither of the Inverdale or Hanna substitutions were seen in wildtype animals, nor was the Inverdale substitution seen in Hanna animals or vice versa.

#### **Table 1.**

Sequencing identification of single base substitutions in Inverdale and Hanna animals.

25 Animals are of known genotype from well-characterised pedigrees (+ = wildtype allele, I = Inverdale allele, H = Hanna allele, Y = Y-chromosome). Numerals indicate the number of times an independent sequence from that animal identified the appropriate sequence variation.

5	Genotype	Animal		Hanna		Inverdale
		ID	Cag (wt)	Tag	gTc (wt)	gAc
	IY ram	667	2			2
	IY ram	3432	1			1
	II ewe	2663	1			1
10	HY ram	9513		3	3	
	HY ram	4864		1	1	
	HH ewe	7133		2	2	
	HI ewe	7141	2	2	2	2
	HI ewe	4865	1	1	1	1
15	H+ ewe	7151	1	1	1	
	I+ ewe	2682	1		1	1
	+Y Romney	7610	2			2
	++ Romney	2884	2			2
	++ Romney	2958	2			2
20	+Y Romney	1079	1			1
	+Y Merino	100	2			2
	++ Merino	121	1			1

A restriction enzyme search revealed that the Hanna base substitution produced a SpeI enzyme cleavage site (a/ctagt) and removed a BsrSI (actg/gn) site around that substitution. These cleavage sites were confirmed by demonstrating that the enzyme SpeI was able to cleave a 541bp PCR fragment spanning this region into 476bp and 65bp fragments in HY and HH animals, but not in IY and +Y animals. In a sheep carrying one copy of both the Inverdale and the Hanna genes (HI), both the 541bp and 476bp fragments were identified.

Similarly BsrS1 was shown to cleave fragments from IY and +Y animals but not HY, and the HI sheep showed a mixture of both bands.

No enzyme cleavage sites are generated or removed from around the Inverdale base substitution site, so a forced RFLP primer was generated which introduces an XbaI cleavage site (t/ctaga) into the PCR product generated from an Inverdale allele, but not a wildtype. The PCR product containing the introduced XbaI site is only produced when the Inverdale A mutation is present, and is not present in Hanna or wildtype animals. In



- 5     this case the PCR product is cleaved by Xba1, removing 30 bases, and resulting in a size change in the length of the final product.

Inverdale DNA strand..TTTCAAGACAGCTT..

30b PCR primer ending-tttct

Produces Xba1 cut site tctaga in final PCR product

- 10    Using this method PCR fragments from 2 HY, 1 HH, 2 +Y and 3 ++ animals were not cleaved by Xba1, while fragments from 36 II and 12 IY animals were cleaved. One HI and 47 I+ animals showed a mixture of cleaved and uncleaved fragments, as expected for heterozygotes.

### Sequencing and Mutation Detection

- 15    We sequenced sheep GDF-9B gene sequences from cDNA and genomic DNA, using primers designed from human, mouse and sheep sequences (Galloway *et al.*, 2000). The sheep gene is similar to human, mouse and rat (Laitinen *et al.*, 1998; Dube *et al.*, 1998; Aaltonen *et al.*, 1999; Jaatinen *et al.*, 1999), with gene features typical of other members of the TGF $\beta$  superfamily. The full-length 1179 bp sequence encodes a 393 amino acid
- 20    prepropeptide (Figure 4) spanning two exons separated by an intron of approximately 5.4 kb. A 25 amino acid predicted signal peptide precedes a 244 amino acid proregion and a putative 125 amino acid C-terminal mature peptide region beyond the RRAR protease cleavage site. The sheep coding region is 82.9% homologous with human, 78.8% with mouse and 78.4% with rat at the nucleotide level.
- 25    We also sequenced genomic DNA in Inverdale (*FecX<sup>I</sup>*) and Hanna (*FecX<sup>H</sup>*) carriers (Figure 5). A single C→T transition at nucleotide position 67 of the mature peptide coding region of *FecX<sup>H</sup>* carriers introduces a premature stop codon in the place of glutamic acid (Q) at amino acid residue 23 (residue 291 of the unprocessed protein). Premature truncation so early in the mature peptide in *FecX<sup>H</sup>* carriers is likely to result

5 in complete loss of GDF-9B function. A distinct single T→A transition occurs in *FecX<sup>f</sup>* carriers at nucleotide position 92 of the mature peptide. The mutation substitutes the valine (V) with aspartic acid (D) at residue 31 (residue 299 of unprocessed protein). The *FecX<sup>f</sup>* mutation is a non-conservative change in a highly conserved region of the protein. All other members of the TGFβ superfamily from a wide range of species contain only  
10 the conserved hydrophobic amino acids valine, isoleucine or leucine at this position (Figure 6).

### Mapping of GDF-9B in sheep

In order to locate *FecX<sup>f</sup>* we generated a genetic linkage map of the sheep X-chromosome (Galloway *et al.*, 1996), and we have mapped the *FecX<sup>f</sup>* locus between flanking markers  
15 10 cM apart at the centre of the sheep X-chromosome (Figure 7). Linkage relationships with the Inverdale phenotype were observed in a family of 177 animals in a three-generation structure with a maximum of 96 informative female meioses. Linkage mapping indicated that *FecX<sup>f</sup>* mapped to a region containing *TIMP1* and *MAOA* (syntenic with human Xp11.2-11.4) and not the region containing *PHKA1*, *XIST* and  
20 *ATP7A* (human Xq13). A breakpoint near *OarMPL* in sheep appears to separate these two groups of genes belonging to distinct syntenic groups on the human and mouse X-chromosomes. *GDF-9B* maps to human Xp11.2 and to a syntenic region of the mouse X-chromosome (Dube *et al.*, 1998; Aaltonen *et al.*, 1999). We have mapped sheep *GDF-9B* into the same 10 cM interval as *FecX<sup>f</sup>* in our Inverdale mapping pedigree, and found  
25 no recombinants between the *FecX<sup>f</sup>* phenotype and *BMP15* out of 78 co-informative female meioses refer Table 2.

**Table 2.**

Linkage of *FecX<sup>f</sup>* to genes and markers on the sheep X-chromosome

Marker	Number of	Co-informative	Recombination	Lod score
	recombinants	meioses	fraction (θ)	(female)
30				

5

	TGLA68	7	176	0.17	4.20
	MAOA	2	143	0.15	1.49
	McM551	9	196	0.07	11.61
	GDF-9B	0	213	0	23.18
10	TIMP1	0	177	0	12.34
	TGLA54	0	170	0	10.54
	OarMP1	1	206	0.01	18.79
	ATP7A	1	147	0.08	2.08
	XIST	2	148	0.13	2.20
15	PHKA1	4	176	0.08	8.47
	OarAE133	5	211	0.07	14.57

CRIMAP Two point linkage analysis to *FecX<sup>I</sup>* phenotype in Inverdale mapping pedigree

No significant sequence differences were found between the *TIMP1* coding DNA of wildtype and *FecX<sup>I</sup>* sheep and identification of a subsequent recombinant among additional *FecX<sup>I</sup>* carriers eliminated *TIMP1* as a candidate for *FecX<sup>I</sup>*.

#### Use of Isolated polypeptide and antibody to manipulate ovulation.

An *E. coli* -derived mature protein of GDF-9B comprising a wildtype sequence as set out in SEQ ID No: 10 was chemically conjugated to the protein Keyhole Limpet Haemocyanin (KLH), and this antigen in Freund's Complete Adjuvant (FCA) was injected subcutaneously (sc) into 10 anoestrous Romney ewes (0.4 mg/ewe). A further

5 9 anoestrous Romney ewes were injected with KLH alone (sc) in FCA to serve as controls (0.4 mg/ewe). Thereafter all animals were injected at monthly intervals with booster antigen (. 0.2 mg/ewe KLH-GDF9B or 0.2 mg/ewe KLH) in a Span, Tween, oil adjuvant. As the ewes entered the breeding season, some 3-4 months after initiating the immunisations, the animals showing oestrous behaviour, as detected by a vasectomised  
 10 ram with marking harness, were subjected to a laparoscopy procedure to visualise the number of corpora lutea (i.e. ovulation sites) on the surface of the ovaries. Seven of the 10 KLH-GDF-9B treated animals and all of the 9 KLH treated animals showed oestrous behaviour. The mean ovulation rates in the KLH-GDF9B and KLH immunised sheep which showed oestrous activity are shown in Table 3.

15 **Table 3.**

Mean ovulation rate in sheep\* showing oestrous activity following repeated immunisation with Keyhole Limpet Haemocyanin (KLH) or KLH conjugated to an *E. coli* expressed GDF9B antigen

Treatment	Geometric mean ovulation rate (95% confidence rate)	Number of sheep showing oestrous activity
KLH	1.4 (1.2, 1.7)	9
KLH-GDF9B	4.5 (2.7, 7.5)	7

The KLH-GDF-9B animals showed a highly significant increase in ovulation rate  
 20 compared to the KLH control animals ( $p < 0.001$ ) ANOVA.

+Evidence that the increased ovulation rate in the KLH-GDF-9B animals that showed oestrus was associated with an antibody response to GDF-9B is shown in Table 4.

5 **Table 4.**

Mean (range) antibody levels in sheep plasma before or after repeated immunisation of female sheep with KLH or KLH conjugated to an *E. coli*-derived GDF-9B mature peptide. The values presented show the absorbance at 490 nm which represents the levels of antibody to GDF-9B

10

Treatment	Preimmune	Immune
KLH	<0.3	<0.3
KLH-GDF-9B ( <i>E. coli</i> expressed mature protein)	<0.3	1.932 (1.454-2.613)

15

Antibody levels were measured by an ELISA procedure after the sheep plasmas were diluted 1:5000. The ELISA method involved coating a 96-well plate with 100 ng/well of an *E. coli* expressed full-length GDF-9B and incubation with 100 µl of diluted sheep plasma and 100 µl of assay buffer, after appropriate blocking treatment and successive washes. After incubation with the sheep plasma and several washes, rabbit anti-sheep-HRP was added for 1 h at 37°C. The wells were then washed and developed with o-phenylenediamine plus hydrogen peroxide with development being stopped with sulphuric acid.

20

In a separate study to demonstrate that a functional variant of ovine GDF-9B will influence ovarian follicular development, 10 female mice were immunised intraperitoneally (ip) with an *E. coli*-derived mature ovine GDF-9B protein (0.2 mg) in FCA (0.22 ml), and another 10 female mice were immunised with bovine alpha lactalbumin (0.2 mg) in FCA (0.22 ml ip) to serve as controls. Subsequently, 3 booster injections of the appropriate antigens (0.1 mg at first booster and 0.05 mg at second and third booster) were given at 2 week intervals in a Span/Tween/oil mixture and the

25

- 5 animals sacrificed 1 week after the final booster. Thereafter the ovaries were fixed in Bouin's aqueous fixative and processed for morphometric analysis. The total number of growing ovarian preantral and antral follicles was determined using a systematic random sampling procedure. The data are summarised in Table 5.

**Table 5.**

- 10 Mean numbers of preantral and antral follicles in mouse ovaries following immunisation with ovine GDF9B or bovine alpha lactalbumin

Treatment	Preantral or antral follicles	Geometric mean number of follicles (95% confidence limits)
Bovine $\alpha$ -lactalbumin	Preantral	329 (291, 371)
	Antral	80 (55, 115)
GDF9B	Preantral	261 (233, 292)
	Antral	84 (57, 124)

- The number of preantral follicles in the GDF9B treated animals was significantly lower than that in the bovine  $\alpha$ -lactalbumin treated mice,  $p < 0.005$  (ANOVA). There were no significant differences between the treatment groups with respect to the number of antral follicles.
- 15



5 Evidence that the differences in number of preantral follicles was associated with an antibody response to GDF-9B is as follows. The mean (range) antibody level in mouse serum diluted 1:50,000, following repeated immunisation was 2.18 (1.28-2.90) whereas all mice immunised with  $\alpha$ -lactalbumin had no response (i.e.  $<0.1$ ). The antibody values, represented by the absorbance at 490 nm, were measured by an ELISA  
10 procedure.

In a further study we induced sterility in recipient animals by the administration of an antigen corresponding to an ovine GDF-9B peptide sequence. To achieve sterility a 15-mer amino acid peptide sequence corresponding to a variant of the mutated and wild-type ovine GDF-9B mature region was synthesised together with a C-terminal cysteine  
15 for conjugation to Keyhole Limpet Haemocyanin (KLH) to generate the antigen. The peptide sequence we utilised was: SEVPGPSREHDGPESC. In this study, 10 anoestrous Romney ewes were injected with 0.4 mg/ewe of the KLH-GDF-9B peptide antigen in Freund's complete adjuvant, and 9 anoestrous Romney ewes were injected with 0.4 mg/ewe KLH antigen as a control group. Subsequently at monthly intervals on 6  
20 occasions, the animals were boosted with further antigen (0.2 mg/ewe on each occasion) in a Span/Tween/oil mixture (sc) and oestrous activity monitored 2-3 times weekly using vasectomised rams. The ovulation rate as assessed by laparoscopy was examined around 1 week before the final booster treatment.

All 9 KLH treated ewes displayed regular cyclical oestrous activity, whereas only 1 out  
25 of the 10 KLH-GDF-9B peptide treated animals showed oestrous activity. The geometric mean (and 95% confidence limits) for ovulation rate in the KLH control animals was 1.5 (1.1, 1.9), whereas in the 9 KLH-GDF-9B peptide treated animals which did not show oestrous the ovulation rate was zero. In the one KLH-GDF-9B peptide treated animal displaying oestrous activity, the ovulation rate was 5. These data  
30 unequivocally show that sterility can be induced by the administration of antibody or mutated GDF-9B antigen or a variant thereof.

- 5 Evidence to support the claim that the induction of an ovulation in the 9 KLH-GDF-9B (16 mer) (i.e. 15 mer + c-terminal cysteine) peptide refer SEQ ID NO: 11 treated animals which did not show oestrus was associated with an antibody response to GDF-9B is shown in Table 3c.

**Table 6.**

- 10 Mean (range) antibody levels in sheep plasma before or after repeated immunisation of female sheep with KLH or KLH conjugated to a GDF-9B 16 mer peptide. The values presented show the absorbance at 490 nm which represents the level of antibody to GDF-9B

Treatment	Preimmune	Immune
KLH	<0.3	<0.3
KLH-GDF-9B (16 mer peptide)	<0.3	2.392 (1.085-3.000)

- 15 Antibody levels were measured by an ELISA procedure as summarised for Table 4.

Collectively these results demonstrate that by administering a GDF-9B antigen the resultant production of antibody in the recipient animals may lead to altered ovarian follicular activity and thus effect modulation of the ovulation rate.

**DNA test for mutations.**

- 20 Sequence variants in the gene for GDF-9B can be determined by a variety of methods, well known to researchers skilled in the art, which are specifically designed to identify differences between alleles of the gene. In particular these methods can be used to identify the Inverdale (*FecX<sup>I</sup>*) and Hanna (*FecX<sup>H</sup>*) single nucleotide polymorphisms

5 (SNPs), namely the C→T transition in *FecX<sup>H</sup>* carriers and the T→A transition occurs in *FecX<sup>I</sup>* carriers, but such methods can also be applied to other alleles of this gene which may be present in other mammals. Samples can be obtained either from DNA or directly from punches of whole blood spotted directly onto FTA® paper or from hair or wool follicles.

10 One such method involves the use of restriction enzymes to cleave the DNA specifically for one allele and not the other, or to cleave a PCR fragment containing a primer which has been designed to contain a cleavage site in combination with one allele or the other.

The *FecX<sup>H</sup>* C→T substitution results in loss of a *Bsr*SI restriction site (actg/gn) and gain  
 15 of a *Spe*I site (a/ctagt). We confirmed this base substitution by demonstrating *Spe*I cleavage of a 541 bp PCR product spanning this region into 476 and 65 bp fragments in *FecX<sup>H</sup>/FecX<sup>H</sup>* females and *FecX<sup>H/Y</sup>* males, but not in *FecX<sup>I</sup>* and wildtype animals. In sheep carrying a copy of each allele (*FecX<sup>I</sup>/FecX<sup>H</sup>*) all three fragments were identified (541, 476 and 65bp). Similarly, *Bsr*SI cleaved fragments from *FecX<sup>I</sup>* and wildtype  
 20 animals but not *FecX<sup>H</sup>* carriers.

A 154 bp PCR product from DNA of *FecX<sup>I</sup>* carriers (produced from primers:

#12 (GAAGTAACCAGTGTTCCCTCCACCCTTTTCT); and

#13 (CATGATTGGGAGAATTGAGACC))

generated a forced *Xba*I restriction site. *Xba*I (t/ctaga) cleaved PCR products generated  
 25 from *FecX<sup>I</sup>/FecX<sup>I</sup>* females and *FecX<sup>I/Y</sup>* males carrying the A allele (tctaga), but not wildtype or *FecX<sup>H</sup>* PCR products carrying the T allele (tctagt). Thus *Xba*I cleaved the 154 bp PCR product to a 124 bp fragment by removing the 30 nucleotide primer #12 only in *FecX<sup>I</sup>* carriers Figure 8.

Products were detected by electrophoresis in 3% FMC Metaphor agarose gels containing

5 ethidium and visualised under ultraviolet light.

Another SNP detection method includes the use of fluoroescntly-labelled primers in conjunction with the forced RFLP method above, and visualising the products on a sequencing machine such as the ABI377.

Other methods for SNP detection include the use of either the Taqman® Allelic  
10 Discrimination method or the SnaPshot™ ddNTP Primer Extension Kit (insert  
manufacturers details here). The Taqman allelic discrimination employs a probe  
technology that exploits the 5'-3' nuclease activity of AmpliTaq Gold® DNA  
polymerase to allow direct detection of the PCR product by the release of a fluorescent  
reporter as a result of PCR. Two probes are used in the allelic discrimination assay, one  
15 probe for each allele, with each probe containing a different reporter dye. The SnaPshot  
system is based on the dideoxy single nucleotide (fluoroescntly labelled) extension of  
an unlabelled oligonucleotide primer for the detection of single nucleotide  
polymorphisms (SNPs). Another SNP detection method employs mass spectrometry  
whereby the region around the SNP or mutation is amplified by PCR and an  
20 oligonucleotide primer is extended through the SNP or mutation in the presence of  
dideoxynucleotides. SNP variants are detected on the basis of mass difference.

It will be apparent to the person skilled in the art that while the invention has been  
described in some detail for the purposes of clarity and understanding, various  
modifications and alterations to the embodiments and methods described herein may be  
25 made without departing from the scope of the inventive concept disclosed in this  
specification and the appended claims.

References cited herein are listed on the following pages, and are incorporated herein  
by this reference.

## 5 REFERENCES

- Aaltonen, J., Laitinen, M. P., Vuojolainen, K., Jaatinen, R., Horelli-Kuitunen, N., Seppa, L., Louhio, H., Tuuri, T., Sjoberg, J., Butzow, R., Hovata, O., Dale, L. and Ritvos, O. (1999) Human growth differentiation factor 9 (GDF-9) and its novel homolog GDF-9b are expressed in oocytes during early folliculogenesis. *J. Clin Endocrinol Metab* 84: 2744-2750
- Amer, P.R., McEwan, J.C., Dodds, K.G. and Davis, G.H. 1998: Cost benefit analysis of commercial use of the Inverdale prolificacy gene in sheep. *Proceedings of the New Zealand Society of Animal Production* 58: 157-160.
- Braw-Tal, R., McNatty, K.P., Smith, P., Heath, D.A., Hudson, N.L., Phillips, D.J., McLeod, B.J. and David, G.H. 1993: The ovaries of ewes homozygous for the X-linked Inverdale gene ( $FecX^I$ ) are devoid of secondary and tertiary follicles but contain many abnormal structures. *Biology of Reproduction* 49: 895-907.
- Davis, G.H., McEwan, J.C., Fennessy, P.F., Dodds, K.G. and Farquhar, P.A. 1991: Evidence for the presence of a major gene influencing ovulation rate on the X-chromosome of sheep. *Biology of Reproduction* 44: 620-624.
- Davis, G.H., McEwan, J.C., Fennessy, P.F., Dodds, K.G., McNatty, K.P. and O, W-S. 1992: Infertility due to bilateral ovarian hypoplasia in sheep homozygous ( $FecX^I FecX^I$ ) for the Inverdale prolificacy gene located on the X-chromosome. *Biology of Reproduction* 46: 636-640.
- Davis, G.H., Bruce, G.D. and Reid, P.J. 1994: Breeding implications of the streak ovary condition in homozygous ( $FecX^I FecX^I$ ) Inverdale sheep. *Proceedings of the 5<sup>th</sup> World Congress on Genetics Applied to Livestock Production*. 19: 249-252.

- 5 Davis, G.H., McEwan, J.C., Fennessy, P.F., Dodds, K.G. 1995: Discovery of the Inverdale gene (FecX). Proceedings of the New Zealand Society of Animal Production 55: 289-290.
- Dong J., Albertini D.F., Nishimori K., Rajendra Kumar T., Lu N. & Matzuk M.M. 1996: Growth differentiation factor-9 is required during early ovarian folliculogenesis. Nature  
10 383: 531-535.
- Dube, J.L., Wang, P., Elvin, J., Lyons, K.M., Celeste, A.J. and matzuk, M.M. 1998: The bone morphogenic protein 15 gene is X-linked and expressed in oocytes. Molecular Endocrinology 12: 1809-1817.
- Galloway, S.M., Hanrahan, V., Dodds, K.G., Potts, M.D., Crawford, A.M. and Hill, D.F.  
15 1996: A linkage map of the ovine X chromosome. Genome Research 6: 667-677.
- Galloway, S.M., Cambridge, L.M., Henry, H.H., van Stijn, T.C. and Davis, G.H. 1999: A genetic test to identify carriers of the ovine Inverdale fecundity gene. Proceedings of the New Zealand Society of Animal Production 59: 114-116.
- Galloway, S.M., McNatty, K.P., Cambridge, L.M., Laitinen, M.P.E., Juengel. J.L.,  
20 Jokiranta, T.S., McLaren, R.J., Luiro, K., Dodds, K.G., Montgomery, G.W., Beattie, A.E., Davis, G.H., and Ritvos, O. (2000) Mutations in an oocyte-derived growth factor gene (BMP15) cause increased ovulation rate and infertility in a dosage-sensitive manner. Nature Genetics 25: 279-283
- Gray, A.J. and Davis, G.H. Commercial performance of sheep carrying the Inverdale  
25 gene (FecX). Proceedings of the New Zealand Society of Animal Production 55: 294-295.
- Hanna, M.M. 1995: Living with the Inverdale gene (FecX) in a Romney flock. Proceedings of the New Zealand Society of Animal Production 55: 296-297.
- Jaatinen, R., Laitinen, M.P., Vuojolainen, K., Aaltonen, J., Louhio, H., Heikinheimo, K.,



- 5 Lehtonen, E. and Ritvos, O. (1999) Localisation of growth differentiation factor-9 (Gdf-9) mRNA and protein in rat ovaries and cDNA cloning of rat GDF-9 and its novel homolog GDF-9B. *Mol Cell Endocrinol* 156: 189-193
- Laitinen, M, Vuojolainen, K., Jaatinen, R., Ketola, I., Aaltonen, J., Lehtonen, E., Heikinheimo, M. and Ritvos, O. 1998: A novel growth differentiation factor-9 (GDF-9)  
10 related factor is co-expressed with GDF-9 in mouse oocytes during folliculogenesis. *Mechanisms of Development* 78: 135-140.
- McNatty, K.P., Smith, P., Hudson, N.L., Heath, D.A., Tisdall, D.J., O, W-S., Braw-Tal, R. 1995: Development of the sheep ovary during foetal and early neonatal life and the effect of fecundity genes. *Journal of Reproduction and Fertility, Supplement* 49: 123-  
15 135.
- McNatty, K.P., Smith, P., Hudson, N.L., Lun, S., Heath, D., Shackell, G and Corrigan, K. 1995: Ovarian characteristics in Inverdale ewes heterozygous (I+) and homozygous (II) for the Inverdale gene (FecX). *Proceedings of the New Zealand Society of Animal Production* 55: 301-303.
- 20 Montgomery, G.W. and Sise, J.A. 1990: Extraction of DNA from sheep white blood cells. *New Zealand Journal of Agricultural Research* 33: 437-441.
- Mouse Genome Database (MGD), Mouse Genome Informatics, The Jackson Laboratory, Bar Harbor, Maine (October 1999).
- World Wide Web (URL: <http://www.informatics.jax.org/>).
- 25 Ohno, S. 1973: Ancient linkage groups and frozen accidents. *Nature* 244: 259-262.
- Sadighi, M., Montgomery, G.W., Bodensteiner, K.J., and Galloway, S.M. 1998: The growth differentiation factor-9 maps to sheep chromosome 5. *Proceedings of the 26th International Conference on Animal Genetics, Auckland, New Zealand, abstract C020.*

- 5 Smith, P., O, W-S., Corrigan, K.A., Smith, T., Lundy, T., David, G.H. and McNatty, K.P. 1997: Ovarian morphology and endocrine characteristics of female sheep fetuses that are heterozygous or homozygous for the Inverdale prolificacy gene (FecX<sup>1</sup>). *Biology of Reproduction* 57: 1183-1192.

**5     WHAT WE CLAIM IS:**

1.     An isolated mutated GDF-9B nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:
  - a)   SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, or SEQ ID NO: 7;
  - b)   a sequence able to hybridise under stringent conditions to the molecule(s) in  
10        (a);
  - c)   a sequence which is functional variant or fragment of the molecule(s) defined  
      in (a);
  - d)   a sequence complementary to the molecule(s) defined in (a), (b) or (c); and
  - e)   an anti-sense sequence corresponding to any of the molecule(s) in (a) – (d).
- 15    2.     A genetic marker for DNA-assisted selection for enhanced ovulation or sterility in a mammal, comprising a nucleic acid molecule which specifically hybridises to a nucleotide sequence of claim 1 or to genomic DNA encoding or associated with a mutated GDF-9B gene.
3.     A genetic marker as claimed in claim 2, wherein the mammal is selected from  
20        the group consisting of humans, sheep, cattle, goats, deer, horses, camelids, possums, pigs, mice, rats, rabbits, hares weasels, ferrets, cats and dogs.
4.     A probe capable of specifically hybridising to a nucleotide sequence(s) of claim 1.
5.     A primer capable of specifically hybridising to the nucleotide sequence(s) of  
25        claim 1.
6.     A vector comprising a nucleic acid molecule(s) of claim 1.

- 5     7.     A construct comprising the nucleic acid molecule(s) of claim 1.
8.     A host cell which has been transformed by a vector or construct as claimed in claim 6 or 7.
9.     An isolated polypeptide comprising an amino acid sequence selected from the group consisting of :
- 10     a)   SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, or
- b)   a functional variant or fragment of the sequence(s) in (a).
10.     An isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 10, or a functional fragment or variant thereof.
11.     An isolated nucleic acid molecule encoding a polypeptide as claimed in claim
- 15     9.
12.     A method of identifying a mammal which carries a mutated nucleic acid molecule encoding GDF-9B, said method comprising the steps of:
- (i)     obtaining a tissue or blood sample from the mammal;
- (ii)    isolating DNA from the sample; and optionally
- 20     (iii)    isolating GDF-9B DNA from DNA obtained at step (i);
- (iv)    probing said DNA with a probe complementary to the mutated GDF-9B DNA of claim 1 or 11;
- (v)     amplifying the amount of mutated GDF-9B DNA; and/or
- (vi)    determining whether the GDF-9B sequence DNA obtained in Step (ii) carries a mutation associated with sterility, or increased or decreased
- 25     ovulation.

- 5 13. A method according to claim 12, in which the mammal is male or female, and carries a single copy of the mutated GDF-9B nucleic acid molecule.
14. A method according to claim 13, in which the mammal is female, and carries two copies of the mutated GDF-9B nucleic acid molecule.
15. A method as claimed in any one of claims 12 – 14, wherein the mammal is  
10 selected from the group consisting of humans, sheep, cattle, goats, deer, horses, camelids, possums, pigs, mice, rats, rabbits, hares weasels, ferrets, cats and dogs.
16. A method of modulating the ovulation rate of a female mammal, said method comprising the step of administering to said mammal an effective amount of an agent selected from the group consisting of:
- 15 a) a polypeptide as claimed in claim 9, or  
b) a polypeptide as claimed in claim 10.
17. A method of increasing the ovulation rate of a female mammal which does not carry a mutated GDF-9B nucleic acid molecule, comprising the step of administering to said mammal an effective amount of a polypeptide as claimed  
20 in claim 9.
18. A method of increasing the ovulation rate of a sterile female mammal which carries two copies of the mutated GDF-9B nucleic acid molecule, comprising the step of administering to said mammal an effective amount of a polypeptide as claimed in claim 10.
- 25 19. A method of increasing or reducing the ovulation rate or inducing sterility in a female mammal, comprising the step of administering an effective amount of an agent selected from the group consisting of:
- a) an immunising-effective amount of a wild type or mutated GDF-9B

- 5 polypeptide comprising an amino acid sequence as claimed in claim 9 or 10;
- b) an anti-sense nucleic acid molecule directed against a nucleic acid encoding a wild type or mutated GDF-9B polypeptide comprising the amino acid sequence as claimed in claim 9 or 10;
- c) a ligand which binds to, or an antigen of, the wild type or mutated GDF-9B
- 10 polypeptide comprising an amino acid sequence as claimed in claim 9 or 10;

thereby to inhibit the biological activity of the mutated or wild type GDF-9B polypeptide.

20. A method as claimed in claim 18 or 19, wherein the female mammal is selected
- 15 from the group consisting of: humans, sheep, cattle, goats, deer, horses, camelids, possums, pigs, mice, rats, rabbits, hares weasels, ferrets, cats and dogs.
21. A composition comprising an effective amount of a polypeptide as claimed in claim 9, together with a pharmaceutically or veterinarily acceptable carrier or diluent.
- 20 22. A composition comprising an effective amount of an agent selected from the group consisting of:
- a) a wild type or mutated GDF-9B polypeptide comprising an amino acid sequence as claimed in claim 9 or 10;
- b) an anti-sense nucleic acid molecule directed against the polypeptide(s)
- 25 according to (a);
- c) a ligand which binds to, or an antigen of, the polypeptide(s) according to (a);
- together with a pharmaceutically or veterinarily acceptable carrier or diluent.



- 5     23.     A ligand which binds to a polypeptide as claimed in claim 9.
24.     A ligand as claimed in claim 23, wherein the ligand is an antibody or an antibody fragment containing the antigen-binding domain.
25.     A ligand as claimed in claim 24, wherein the ligand is a monoclonal antibody.
26.     A ligand as claimed in claim 24, wherein the ligand is a phage display molecule.
- 10    27.     The use of a nucleic acid molecule as claimed in claim 1 to identify sequence variants in an individual mammal associated with increased ovulation, reduced ovulation or the sterility of that mammal.
28.     A kit for identifying mammals which carry a mutated GDF-9B nucleic acid molecule, said kit comprising:
- 15     a)     primer pairs for amplification of the appropriate region of the GDF-9B; and optionally one or more of the following
- 20     b)     buffer solution for the DNA amplification;
- 20     c)     a mixture of deoxynucleotides;
- 20     d)     means for DNA amplification;
- 20     e)     control DNA from the species being tested;
- 20     f)     appropriate standards; and
- 20     g)     a detection system.
29.     An isolated nucleic acid molecule comprising a nucleotide sequence as set forth in SEQ ID NO: 9, or a functionally active fragment or variant thereof.
- 25    30.     An isolated functional variant polypeptide as set forth in SEQ ID NO: 11.

- 5     31.     An isolated nucleic acid molecule comprising a nucleic acid sequence as set forth  
in SEQ ID NO: 12 or SEQ ID NO: 14 or a functional variant or fragment of  
either sequence.
32.     An isolated polypeptide as set forth in SEQ ID NO: 13 or SEQ ID NO: 15, or a  
functional variant or fragment of either sequence.
- 10    33.     An isolated nucleic acid molecule comprising a nucleotide sequence as set forth  
in SEQ ID NO: 16, or a functionally active fragment or variant thereof.
34.     An isolated polypeptide having an amino acid sequence as set forth in SEQ ID  
NO: 17, or a functional fragment or variant thereof.
- 15    35.     A method for reducing the ovulation rate or inducing sterility in a possum  
comprising the step of administering an effective amount of a polypeptide as  
claimed in claim 34.
36.     An isolated nucleic acid molecule substantially as described herein with  
reference to any example and/or drawing thereof.
- 20    37.     An isolated polypeptide substantially as described herein with reference to any  
example and/or drawing thereof.
38.     A vector incorporating an isolated nucleic acid molecule of the present invention  
substantially as described herein with reference to any example and/or drawing  
thereof.
- 25    39.     A ligand which binds to a polypeptide of the present invention substantially as  
described herein with reference to any example and/or drawing thereof.
40.     A method for identifying a mammal which carries a mutated nucleic acid  
molecule substantially as described herein with reference to any example and/or  
drawing thereof.

- 5     41.     A method of modulating the ovulation rate of a female mammal substantially as described herein with reference to any example and/or drawing thereof.
42.     A composition substantially as described herein with reference to any example and/or drawing thereof.
43.     The use of a nucleic acid molecule of the present invention to identify sequence  
10           variants substantially as described herein with reference to any example and/or drawing thereof.
44.     A kit for identifying mammals which carry a mutated GDF-9B nucleic acid molecule substantially as described herein with reference to any example and/or drawing thereof.




Figure 1

Figure 2a

Single base mutation within the GDF-9B gene in Inverdale sheep

CTTCACCTAACTCATTCCCACCTCTCCTGCCATGTGGAGCCCTGGGTCCAGAAAAGCCCAAC  
CAATCACTTTCGTTCTTCAGAAAGAGGCTCCTCAAAGCCTTCCTTGTGGCCAAAACCTTGA  
CAGAGATGGATATCATGGAACATGTTGGGCAAAGCCTCTGGAATCACAAGGGGGCCAGGGTT  
CTACGACTCCGCTTCGTGTCTCAGCAGCCAAGAGGTAAGTGGAGGTTCTTGAGTTCTGGTGGCA  
TGGCACTTCATCATTGGACACTGTCTTCTTGTAGTGTATTTCATGACACTCAGAGTGTTC  
AGAAGACCAAACCTCTCCGTAAAGGGCTGAAAGAGTTTACAGAAAAGACCCCTTCTCTTCTC  
TTGAGGAGGGCTCGTCAAGCAGGCAGTATTGCATCGGAAGTTCTGGCCCTCCAGGGAGCA  
TGATGGGCCTGAAAGTAACCAAGTGTTCCTCCACCCTTTTCAAGAGAGCTTCCAGGAGCTGG  
GCTGGGATCAGTGGATCATTGCTCCCATCTCTATACCCCAAACTACTGTAAGGGAGTATGT  
CCTCGGGTACTACACTATGGTCTCAATTCTCCCAATCATGCCATCATCCAGAACCTTGTGAG  
TGAGCTGGTGGATCAGAATGTCCCTCAGCCTTCTGTGTCCCTTATAAGTATGTTCCCATTA  
GCATCCTTCTGATTGAGGCAAATGGGAGTATCTTGTACAAGGAGTATGAGGGTATGATTGCC  
CAGTCTTGCACATGCAGGTGAGCGGCAAAGGTGCAGCTAGCTCAG

Figure 2b

Single base mutation within the GDF-9B gene in Hanna sheep

CTTCACCTAACTCATTCCCACCTCTCCTGCCATGTGGAGCCCTGGGTCCAGAAAAGCCCAAC  
CAATCACTTTCGTTCTTCAGAAAGAGGCTCCTCAAAGCCTTCCTTGTGGCCAAAACCTTGA  
CAGAGATGGATATCATGGAACATGTTGGGCAAAGCCTCTGGAATCACAAGGGGGCCAGGGTT  
CTACGACTCCGCTTCGTGTGTCTCAGCAGCCAAGAGGTAAGTGGAGGTTCTTGAGTTCTGGTGGCA  
TGGCACTTCATCATTGGACACTGTCTTCTTGTAGTGTATTTCATGACAGTCAAGAGTGTTC  
AGAAGACCAAACCTCTCCGTAAAGGGCTGAAAGAGTTTACAGAAAAGACCCCTTCTCTTCTC  
TTGAGGAGGGCTCGTCAAGCAGGCAGTATTGCATCGGAAGTTCTGGCCCTCCAGGGAGCA  
TGATGGGCCTGAAAGTAACCAAGTGTTCCTCCACCCTTTTCAAGTCAAGCTTCCAGGAGCTGG  
GCTGGGATCAGTGGATCATTGCTCCCATCTCTATACCCCAAACTACTGTAAGGGAGTATGT  
CCTCGGGTACTACACTATGGTCTCAATTCTCCCAATCATGCCATCATCCAGAACCTTGTGAG  
TGAGCTGGTGGATCAGAATGTCCCTCAGCCTTCTGTGTCCCTTATAAGTATGTTCCCATTA  
GCATCCTTCTGATTGAGGCAAATGGGAGTATCTTGTACAAGGAGTATGAGGGTATGATTGCC  
CAGTCTTGCACATGCAGGTGAGCGGCAAAGGTGCAGCTAGCTCAG

Figure 2c

GGCAGTATTGCATCGGAAGTTCTTGGCCCTCCAGGGAGCATGATGGGCCTGAAAGTAACCA  
GTGTTCCCTGCACCCCTTTTCAAGACAGCTTCCAGGAGCTGGGCTGGGATCAGTGGATCATTC  
CTCCCATCTCTATACCCCAAACTACTGTAAGGGAGTATGTCTTGGGTACTACACTATGGT  
CTCAATTCTCCCAATCATGC

Figure 2d

GGCAGTATTGCATCGGAAGTTCCTGGCCCCCTCCAGGGAGCATGATGGGCCTGAAAGTAACTA  
GTGTTCCCTCCACCCTTTTCAAGTCAGCTTCCAGCAGCTGGGCTGGGATCACTGGATCATTG  
CTCCCCATCTCTATACCCCAAACACTACTGTAAGGGAGTATGTCCTCGGGTACTACACTATGGT  
CTCAATTCTCCCAATCATGC

Figure 2e

...TTT CAA GAC AGC TTC...

Figure 2f

..AGT AAC TAG TGT TCC...

Figure 3a

Deduced amino acid sequence of the GDF -9B Inverdale protein

LHLTHSHLSCHVEPWVQKSPTNHFPSSGRGSSKPSLLPKTWTEMDIMEHVGQKLWNHKGRRV  
LRLRFVCQQPRGSEVLEFWWHGTSSLDTVFLLLYFNDTQSVQTKPLPKGLKEFTEKDPSLL  
LRRARQAGSIASEVPGPSREHDGPESNQCSLHPFQDSFQQLGWDHWIAPHLYTPNYCKGVC  
PRVLHYGLNSPNHAIQNVLVSELVDQNVPQPSCVPYKYVPISILLIEANGSILYKEYEGMIA  
QSCTCR

Figure 3b

Deduced amino acid sequence of the truncated GDF-9B Hanna protein

LHLTHSHLSCHVEPWVQKSPTNHFPSSGRGSSKPSLLPKTWTEMDIMEHVGQKLWNHKGRRV  
LRLRFVCQQPRGSEVLEFWWHGTSSLDTVFLLLYFNDTQSVQTKPLPKGLKEFTEKDPSLL  
LRRARQAGSIASEVPGPSREHDGPESNEND




**FIGURE 4**

Predicted amino acid sequence of sheep GDF9B with human and mouse.

Numbers in brackets above the line indicate amino acid positions of the mature peptide. The open triangle shows the position of the Leu polymorphism; the black triangle indicates the position of the single intron. The RRAR putative processing site and the conserved cysteins are shaded grey. Positions of the FeoX<sup>I</sup> and FeoX<sup>H</sup> mutations at amino acids 23 and 31 are in bold.

Sheep	1.	MVLLSILRL	LW.GVLVFM	HRVQMTQVGO	PSIAHLPEAP	TUPLTQELLE
Human		MVLLSILRL	FLCELVLEME	HRAQMAEGGO	SSIALLAEE	TUPLIEELLE
Mouse		MALLTILRL	LW.GVLVFM	QRVQMAKPGW	PSTALLADDP	TLPSTLDLAK
Sheep	50	EAPGKQQRKP	RVLGHSLRYM	LELYQRSADA	SGHPRENRTI	GATMVRLVVP
Human		ESPGEQPRKE	RLLGHSLRYH	BELYRSADS	HGHPRENRTI	GATMVRLVVP
Mouse		EAPGKE.MKO	WFOGYPLRYM	LKLYRSADP	HGHPRENRTI	GAKMVRLVVP
Sheep	100	LASVARELRG	SWHIQTLDFP	LRPNRVAYQL	VRATVVYRHQ	LHETHSHLSC
Human		LTFVAREHRG	TWHIQILGFP	LRPNRGLYQL	VRATVVYRHH	LQLTRENLSLSC
Mouse		SANTVAREPRG	SWHVQTLDFP	LASNQVAYEL	TRATVVYRHQ	LHLVNVYHLSLSC
Sheep	150	HVEPWVQKSP	TNHPSSSGRG	SSKPSLLPKT	WTENDIMEHV	QOKLWNHKGR
Human		HVEPWVQKNP	TNHPSSSEGD	SSKPSLMSNA	WKEMDITQEV	QORFWANKGH
Mouse		HVETWVPKCR	TKHLPSKSKG	SSKPSPMSEA	WTEIDITHCI	QOKLWNKGR
Sheep	200	RVLRLRFVCO	QPRGSEVLEF	RWEGTSSLDI	VFLLLYFNDT	Q.SVOKTRPL
Human		RILRLRFMCQ	QOKDSGGLLEL	WEGTSSLDI	AFLLLYFNDT	HKSIRKAKFL
Mouse		SVLRLRFMCQ	QOKGNETREF	RWHGMTSLDV	AFLLLYFNDT	DERV.QGKLL
(1)						
FecX <sup>n</sup> Q291Ter						
Sheep	249	PKGLKEPTEK	DPSLLLEKAR	QAGSIASEVP	GPSREHDGPE	SNQSLHPFO
Human		PRGMEEFMR	ES..LLREK	QADGISAET	ASSSKHSGPE	NNQSLHPFO
Mouse		ARGQEELTDR	ESSFLMRVA	QTQSTESDAS	GPSQEHGGSV	NNQSLHPYK
V299D:FecX <sup>1</sup>						
Sheep	299	YSFQQLGWDH	WIIAPHLYTP	NYKGVPRV	LHYGLNSPNH	AIQNLVSEL
Human		ISFRQLGWDH	WIIAPPFYTP	NYKGTILRV	LRDGLNSPNH	ATTQNLINOL
Mouse		VSPHQLGWDH	WIIAPRLYTP	NYKGTETRV	LPYGLNSPNH	AITQSLVNEL
(125)						
Sheep	349	VDQNVPPQPS	VPYKYVPISI	LLIEANGSIL	YKEYEGMIAQ	SETER 393
Human		VDQSVPRPS	VPYKYVPISV	LMIEANGSIL	YKEYEGMIAE	SETER
Mouse		VNHSVPQPS	VPYNFLPMIS	LLIETNGSIL	YKEYEGMIAQ	SETER

**FIGURE 5**


**FIGURE 6**

Alignment of mutated region of predicted FeoXI protein with TGF $\beta$  superfamily members from other species

	289	299	322
sheep BMP15	SNOCSLHPFCVTSFOOLGWDHWLIAPHLYTPNYCKG		
human BMP15	NNQCSLHPFCVTSFRQLGWDHWLIAPPEYTPNYCKG		
zebrafish BMP15	KNNCHLYSPSVDSKDKGWDHWVIAPHKYNPGYCMG		
mouse Gdf9	QNECELHDFRLSFSQEKWDNWIVAFHRYNPRYCKG		
human BMP7	RQACKKHETLYSFRDLGWQDWIIAPEGYAAYYCEG		
sea urchin Univin	TNLCQRHRLEVSFRDVGWENWIIAPMGYQAVYCDG		
rat Inhibin $\beta$ A	VNIQCKKQFFVSEKDIGWNDWIIAPSGYHANYCEG		
chicken TGF $\beta$ 3	EENQCVRPPLYEEPTDLGKRWVHEPKGYFANFCSG		
worm ( <i>C.elegans</i> ) Daf7	SKGQCLYDLEEEFEKIGWDWIVAPRYNAYMCRG		
cattle MIS	DGPALRELSDLRAE...RSVLIPETYQANNQCG		
mouse Gdnf	NRGCVLTATRLNVTDLGLGYETKEELIFR...YCSG		


**FIGURE 7**

Linkage map of region of sheep X chromosome containing the GDF9-B gene



**FIGURE 8**

SNP variant detection of sheep carrying Inverdale *FecX<sup>I</sup>* mutation, and non-carriers, using *Xba*I digestion of a forced PCR fragment. DNA from carriers containing the A allele are cleaved. Cleaved fragments from a ++ non-carrier, an I+ heterozygote and an II homozygote carrier are shown beside heterozygote (samples A1, A2) females, carrier rams (samples A5, A10) and non-carrier rams (samples A3, A4, A6, A7, A8, A11, A12 and A13).



## SEQUENCE LISTING

<110> Agresearch Limited  
 Galloway, Susan  
 McNatty, Kenneth  
 Davis, George  
 Ritvos, Olli

<120> Nucleotide sequences involved in increasing or decreasing mammalian ovulation rate

<130> 30929X144

<150> NZ 500844

<151> 2000-05-05

<160> 17

<170> PatentIn version 3.0

<210> 1

<211> 778

<212> DNA

<213> Ovis aries

<220>

<221> CDS

<222> (1)..(762)

<220>

<221> mat\_peptide

<222> (388)..()

<220>

<221> mutation

<222> (479)..(479)

<223> Inverdale nucleotide a but wildtype nucleotide t, Inverdale codon gac but wildtype codon gt

<220>

<221> misc\_feature

<222> (376)..(387)

<223> furin protease sequence

<220>

<221> misc\_feature

<222> (763)..(765)

<223> stop codon

<400> 1

ctt	cac	cta	act	cat	tcc	cac	ctc	tcc	tgc	cat	gtg	gag	ccc	tgg	45
Leu	His	Leu	Thr	His	Ser	His	Leu	Ser	Cys	His	Val	Glu	Pro	Trp	
				-125					-120					-115	

gtc	cag	aaa	agc	cca	acc	aat	cac	ttt	cct	tct	tca	gga	aga	ggc	90
Val	Gln	Lys	Ser	Pro	Thr	Asn	His	Phe	Pro	Ser	Ser	Gly	Arg	Gly	

-110				-105				-100								
tcc	tca	aag	cct	tcc	ctg	ttg	ccc	aaa	act	tgg	aca	gag	atg	gat	atc	138
Ser	Ser	Lys	Pro	Ser	Leu	Leu	Pro	Lys	Thr	Trp	Thr	Glu	Met	Asp	Ile	
				-95					-90					-85		
atg	gaa	cat	gtt	ggg	caa	aag	ctc	tgg	aat	cac	aag	ggg	cgc	agg	gtt	186
Met	Glu	His	Val	Gly	Gln	Lys	Leu	Trp	Asn	His	Lys	Gly	Arg	Arg	Val	
			-80					-75					-70			
cta	cga	ctc	cgc	ttc	gtg	tgt	cag	cag	cca	aga	ggt	agt	gag	gtt	ctt	234
Leu	Arg	Leu	Arg	Phe	Val	Cys	Gln	Gln	Pro	Arg	Gly	Ser	Glu	Val	Leu	
		-65					-60					-55				
gag	ttc	tgg	tgg	cat	ggc	act	tca	tca	ttg	gac	act	gtc	ttc	ttg	tta	282
Glu	Phe	Trp	Trp	His	Gly	Thr	Ser	Ser	Leu	Asp	Thr	Val	Phe	Leu	Leu	
	-50					-45					-40					
ctg	tat	ttc	aat	gac	act	cag	agt	gtt	cag	aag	acc	aaa	cct	ctc	cct	330
Leu	Tyr	Phe	Asn	Asp	Thr	Gln	Ser	Val	Gln	Lys	Thr	Lys	Pro	Leu	Pro	
-35					-30					-25					-20	
aaa	ggc	ctg	aaa	gag	ttt	aca	gaa	aaa	gac	cct	tct	ctt	ctc	ttg	agg	378
Lys	Gly	Leu	Lys	Glu	Phe	Thr	Glu	Lys	Asp	Pro	Ser	Leu	Leu	Leu	Arg	
				-15					-10					-5		
agg	gct	cgt	caa	gca	ggc	agt	att	gca	tcg	gaa	gtt	cct	ggc	ccc	tcc	426
Arg	Ala	Arg	Gln	Ala	Gly	Ser	Ile	Ala	Ser	Glu	Val	Pro	Gly	Pro	Ser	
	-1	1				5						10				
agg	gag	cat	gat	ggg	cct	gaa	agt	aac	cag	tgt	tcc	ctc	cac	cct	ttt	474
Arg	Glu	His	Asp	Gly	Pro	Glu	Ser	Asn	Gln	Cys	Ser	Leu	His	Pro	Phe	
	15					20					25					
caa	gac	agc	ttc	cag	cag	ctg	ggc	tgg	gat	cac	tgg	atc	att	gct	ccc	522
Gln	Asp	Ser	Phe	Gln	Gln	Leu	Gly	Trp	Asp	His	Trp	Ile	Ile	Ala	Pro	
30					35					40					45	
cat	ctc	tat	acc	cca	aac	tac	tgt	aag	gga	gta	tgt	cct	cgg	gta	cta	570
His	Leu	Tyr	Thr	Pro	Asn	Tyr	Cys	Lys	Gly	Val	Cys	Pro	Arg	Val	Leu	
				50					55					60		
cac	tat	ggt	ctc	aat	tct	ccc	aat	cat	gcc	atc	atc	cag	aac	ctt	gtc	618
His	Tyr	Gly	Leu	Asn	Ser	Pro	Asn	His	Ala	Ile	Ile	Gln	Asn	Leu	Val	
			65					70					75			
agt	gag	ctg	gtg	gat	cag	aat	gtc	cct	cag	cct	tcc	tgt	gtc	cct	tat	666
Ser	Glu	Leu	Val	Asp	Gln	Asn	Val	Pro	Gln	Pro	Ser	Cys	Val	Pro	Tyr	
		80					85					90				
aag	tat	gtt	ccc	att	agc	atc	ctt	ctg	att	gag	gca	aat	ggg	agt	atc	714
Lys	Tyr	Val	Pro	Ile	Ser	Ile	Leu	Leu	Ile	Glu	Ala	Asn	Gly	Ser	Ile	
	95					100					105					
ttg	tac	aag	gag	tat	gag	ggt	atg	att	gcc	cag	tcc	tgc	aca	tgc	agg	762
Leu	Tyr	Lys	Glu	Tyr	Glu	Gly	Met	Ile	Ala	Gln	Ser	Cys	Thr	Cys	Arg	
110					115					120					125	
tgacggcaaa	ggtgca															778



<400> 2

Arg Glu His Asp Gly Pro Glu Ser Asn Gln Cys Ser Leu His Pro Phe  
15 20 25

Gln Asp Ser Phe Gln Gln Leu Gly Trp Asp His Trp Ile Ile Ala Pro  
30 35 40 45

His Leu Tyr Thr Pro Asn Tyr Cys Lys Gly Val Cys Pro Arg Val Leu  
50 55 60

His Tyr Gly Leu Asn Ser Pro Asn His Ala Ile Ile Gln Asn Leu Val  
65 70 75

Ser Glu Leu Val Asp Gln Asn Val Pro Gln Pro Ser Cys Val Pro Tyr  
80 85 90

Lys Tyr Val Pro Ile Ser Ile Leu Leu Ile Glu Ala Asn Gly Ser Ile  
95 100 105

Leu Tyr Lys Glu Tyr Glu Gly Met Ile Ala Gln Ser Cys Thr Cys Arg  
110 115 120 125

<210> 3  
<211> 778  
<212> DNA  
<213> Ovis aries

<220>  
<221> CDS  
<222> (1)..(453)

<220>  
<221> mat\_peptide  
<222> (388)..()

<220>  
<221> mutation  
<222> (454)..(454)  
<223> Hanna nucleotide t but wildtype nucleotide c, Hanna codon tag bu  
t wildtype codon ca

<220>  
<221> misc\_feature  
<222> (376)..(387)  
<223> furin protease sequence

<220>  
<221> misc\_feature  
<222> (454)..(456)  
<223> premature stop codon

<400> 3  
ctt cac cta act cat tcc cac ctc tcc tgc cat gtg gag ccc tgg  
Leu His Leu Thr His Ser His Leu Ser Cys His Val Glu Pro Trp

45

	-125	-120	-115	
gtc cag aaa agc cca acc aat cac ttt cct tct tca gga aga ggc				90
Val Gln Lys Ser Pro Thr Asn His Phe Pro Ser Ser Gly Arg Gly	-110	-105	-100	
tcc tca aag cct tcc ctg ttg ccc aaa act tgg aca gag atg gat atc				138
Ser Ser Lys Pro Ser Leu Leu Pro Lys Thr Trp Thr Glu Met Asp Ile	-95	-90	-85	
atg gaa cat gtt ggg caa aag ctc tgg aat cac aag ggg cgc agg gtt				186
Met Glu His Val Gly Gln Lys Leu Trp Asn His Lys Gly Arg Arg Val	-80	-75	-70	
cta cga ctc cgc ttc gtg tgt cag cag cca aga ggt agt gag gtt ctt				234
Leu Arg Leu Arg Phe Val Cys Gln Gln Pro Arg Gly Ser Glu Val Leu	-65	-60	-55	
gag ttc tgg tgg cat ggc act tca tca ttg gac act gtc ttc ttg tta				282
Glu Phe Trp Trp His Gly Thr Ser Ser Leu Asp Thr Val Phe Leu Leu	-50	-45	-40	
ctg tat ttc aat gac act cag agt gtt cag aag acc aaa cct ctc cct				330
Leu Tyr Phe Asn Asp Thr Gln Ser Val Gln Lys Thr Lys Pro Leu Pro	-35	-30	-25	-20
aaa ggc ctg aaa gag ttt aca gaa aaa gac cct tct ctt ctc ttg agg				378
Lys Gly Leu Lys Glu Phe Thr Glu Lys Asp Pro Ser Leu Leu Leu Arg	-15	-10	-5	
agg gct cgt caa gca ggc agt att gca tcg gaa gtt cct ggc ccc tcc				426
Arg Ala Arg Gln Ala Gly Ser Ile Ala Ser Glu Val Pro Gly Pro Ser	-1 1	5	10	
agg gag cat gat ggg cct gaa agt aac tagtggtccc tccacccttt				473
Arg Glu His Asp Gly Pro Glu Ser Asn	15	20		
tcaagtcagc ttccagcagc tgggctggga tcaactggatc attgctcccc atctctatac				533
cccaaactac tgtaagggag tatgtcctcg ggtactacac tatggtctca attctcccaa				593
tcatgccatc atccagaacc ttgtcagtga gctgggtggat cagaatgtcc ctcagccttc				653
ctgtgtccct tataagtatg ttcccattag catccttctg attgaggcaa atgggagtat				713
cttgtacaag gagtatgagg gtatgattgc ccagtcctgc acatgcaggt gacggcaaag				773
gtgca				778

<210> 4  
 <211> 151  
 <212> PRT  
 <213> Ovis aries

<220>  
 <221> misc\_feature  
 <222> (376)..(387)

<223> furin protease sequence

<220>

<221> misc\_feature

<222> (454)..(456)

<223> premature stop codon

<400> 4

Leu His Leu Thr His Ser His Leu Ser Cys His Val Glu Pro Trp  
-125 -120 -115

Val Gln Lys Ser Pro Thr Asn His Phe Pro Ser Ser Gly Arg Gly  
-110 -105 -100

Ser Ser Lys Pro Ser Leu Leu Pro Lys Thr Trp Thr Glu Met Asp Ile  
-95 -90 -85

Met Glu His Val Gly Gln Lys Leu Trp Asn His Lys Gly Arg Arg Val  
-80 -75 -70

Leu Arg Leu Arg Phe Val Cys Gln Gln Pro Arg Gly Ser Glu Val Leu  
-65 -60 -55

Glu Phe Trp Trp His Gly Thr Ser Ser Leu Asp Thr Val Phe Leu Leu  
-50 -45 -40

Leu Tyr Phe Asn Asp Thr Gln Ser Val Gln Lys Thr Lys Pro Leu Pro  
-35 -30 -25 -20

Lys Gly Leu Lys Glu Phe Thr Glu Lys Asp Pro Ser Leu Leu Leu Arg  
-15 -10 -5

Arg Ala Arg Gln Ala Gly Ser Ile Ala Ser Glu Val Pro Gly Pro Ser  
-1 1 .5 10

Arg Glu His Asp Gly Pro Glu Ser Asn  
15 20

<210> 5

<211> 391

<212> DNA

<213> Ovis aries

<220>

<221> CDS

<222> (1)..(375)

<220>

<221> mutation  
<222> (92)..(92)

<220>  
<221> misc\_feature  
<222> (376)..(378)  
<223> stop codon

<400> 5  
 caa gca ggc agt att gca tcg gaa gtt cct ggc ccc tcc agg gag cat 48  
 Gln Ala Gly Ser Ile Ala Ser Glu Val Pro Gly Pro Ser Arg Glu His  
 1 5 10 15  
 gat ggg cct gaa agt aac cag tgt tcc ctc cac cct ttt caa gac agc 96  
 Asp Gly Pro Glu Ser Asn Gln Cys Ser Leu His Pro Phe Gln Asp Ser  
 20 25 30  
 ttc cag cag ctg ggc tgg gat cac tgg atc att gct ccc cat ctc tat 144  
 Phe Gln Gln Leu Gly Trp Asp His Trp Ile Ile Ala Pro His Leu Tyr  
 35 40 45  
 acc cca aac tac tgt aag gga gta tgt cct cgg gta cta cac tat ggt 192  
 Thr Pro Asn Tyr Cys Lys Gly Val Cys Pro Arg Val Leu His Tyr Gly  
 50 55 60  
 ctc aat tct ccc aat cat gcc atc atc cag aac ctt gtc agt gag ctg 240  
 Leu Asn Ser Pro Asn His Ala Ile Ile Gln Asn Leu Val Ser Glu Leu  
 65 70 75 80  
 gtg gat cag aat gtc cct cag cct tcc tgt gtc cct tat aag tat gtt 288  
 Val Asp Gln Asn Val Pro Gln Pro Ser Cys Val Pro Tyr Lys Tyr Val  
 85 90 95  
 ccc att agc atc ctt ctg att gag gca aat ggg agt atc ttg tac aag 336  
 Pro Ile Ser Ile Leu Leu Ile Glu Ala Asn Gly Ser Ile Leu Tyr Lys  
 100 105 110  
 gag tat gag ggt atg att gcc cag tcc tgc aca tgc agg tgacggcaaaa 385  
 Glu Tyr Glu Gly Met Ile Ala Gln Ser Cys Thr Cys Arg  
 115 120 125  
 ggtgca 391

<210> 6  
<211> 125  
<212> PRT  
<213> Ovis aries

<220>  
<221> misc\_feature  
<222> (376)..(378)  
<223> stop codon

<400> 6  
 Gln Ala Gly Ser Ile Ala Ser Glu Val Pro Gly Pro Ser Arg Glu His  
 1 5 10 15

Asp Gly Pro Glu Ser Asn Gln Cys Ser Leu His Pro Phe Gln Asp Ser  
20 25 30

Phe Gln Gln Leu Gly Trp Asp His Trp Ile Ile Ala Pro His Leu Tyr  
35 40 45

Thr Pro Asn Tyr Cys Lys Gly Val Cys Pro Arg Val Leu His Tyr Gly  
50 55 60

Leu Asn Ser Pro Asn His Ala Ile Ile Gln Asn Leu Val Ser Glu Leu  
65 70 75 80

Val Asp Gln Asn Val Pro Gln Pro Ser Cys Val Pro Tyr Lys Tyr Val  
85 90 95

Pro Ile Ser Ile Leu Leu Ile Glu Ala Asn Gly Ser Ile Leu Tyr Lys  
100 105 110

Glu Tyr Glu Gly Met Ile Ala Gln Ser Cys Thr Cys Arg  
115 120 125

<210> 7  
<211> 391  
<212> DNA  
<213> Ovis aries

<220>  
<221> CDS  
<222> (1)..(66)

<220>  
<221> mutation  
<222> (67)..(67)

<220>  
<221> misc\_feature  
<222> (67)..(69)  
<223> premature stop codon

<400> 7  
caa gca ggc agt att gca tcg gaa gtt cct ggc ccc tcc agg gag cat 48  
Gln Ala Gly Ser Ile Ala Ser Glu Val Pro Gly Pro Ser Arg Glu His  
1 5 10 15

gat ggg cct gaa agt aac tagtggtccc tccacccttt tcaagtcagc 96  
Asp Gly Pro Glu Ser Asn  
20

ttccagcagc tgggctggga tcaactggatc attgctcccc atctctatac cccaaactac 156

tgtaagggag tatgtcctcg ggtactacac tatggtctca attctcccaa tcatgccatc 216  
 atccagaacc ttgtcagtga gctgggtggat cagaatgtcc ctcagccttc ctgtgtccct 276  
 tataagtatg ttcccattag catccttctg attgaggcaa atgggagtat cttgtacaag 336  
 gagtatgagg gtatgattgc ccagtcctgc acatgcaggt gacggcaaag gtgca 391

<210> 8  
 <211> 22  
 <212> PRT  
 <213> Ovis aries

<220>  
 <221> misc\_feature  
 <222> (67)..(69)  
 <223> premature stop codon

<400> 8

Gln Ala Gly Ser Ile Ala Ser Glu Val Pro Gly Pro Ser Arg Glu His  
 1 5 10 15

Asp Gly Pro Glu Ser Asn  
 20

<210> 9  
 <211> 778  
 <212> DNA  
 <213> Ovis aries

<220>  
 <221> CDS  
 <222> (1)..(762)

<220>  
 <221> misc\_feature  
 <222> (376)..(387)  
 <223> furin protease sequence

<220>  
 <221> mat\_peptide  
 <222> (388)..()

<220>  
 <221> misc\_feature  
 <222> (479)..(479)  
 <223> position of Inverdale mutation

<220>  
 <221> misc\_feature  
 <222> (454)..(454)  
 <223> position of Hanna mutation



<220>  
 <221> misc\_feature  
 <222> (763)..(765)  
 <223> stop codon

<400> 9  
 ctt cac cta act cat tcc cac ctc tcc tgc cat gtg gag ccc tgg 45  
 Leu His Leu Thr His Ser His Leu Ser Cys His Val Glu Pro Trp  
 -125 -120 -115  
 gtc cag aaa agc cca acc aat cac ttt cct tct tca gga aga ggc 90  
 Val Gln Lys Ser Pro Thr Asn His Phe Pro Ser Ser Gly Arg Gly  
 -110 -105 -100  
 tcc tca aag cct tcc ctg ttg ccc aaa act tgg aca gag atg gat atc 138  
 Ser Ser Lys Pro Ser Leu Leu Pro Lys Thr Trp Thr Glu Met Asp Ile  
 -95 -90 -85  
 atg gaa cat gtt ggg caa aag ctc tgg aat cac aag ggg cgc agg gtt 186  
 Met Glu His Val Gly Gln Lys Leu Trp Asn His Lys Gly Arg Arg Val  
 -80 -75 -70  
 cta cga ctc cgc ttc gtg tgt cag cag cca aga ggt agt gag gtt ctt 234  
 Leu Arg Leu Arg Phe Val Cys Gln Gln Pro Arg Gly Ser Glu Val Leu  
 -65 -60 -55  
 gag ttc tgg tgg cat ggc act tca tca ttg gac act gtc ttc ttg tta 282  
 Glu Phe Trp Trp His Gly Thr Ser Ser Leu Asp Thr Val Phe Leu Leu  
 -50 -45 -40  
 ctg tat ttc aat gac act cag agt gtt cag aag acc aaa cct ctc cct 330  
 Leu Tyr Phe Asn Asp Thr Gln Ser Val Gln Lys Thr Lys Pro Leu Pro  
 -35 -30 -25 -20  
 aaa ggc ctg aaa gag ttt aca gaa aaa gac cct tct ctt ctc ttg agg 378  
 Lys Gly Leu Lys Glu Phe Thr Glu Lys Asp Pro Ser Leu Leu Leu Arg  
 -15 -10 -5  
 agg gct cgt caa gca ggc agt att gca tcg gaa gtt cct ggc ccc tcc 426  
 Arg Ala Arg Gln Ala Gly Ser Ile Ala Ser Glu Val Pro Gly Pro Ser  
 -1 1 5 10  
 agg gag cat gat ggg cct gaa agt aac cag tgt tcc ctc cac cct ttt 474  
 Arg Glu His Asp Gly Pro Glu Ser Asn Gln Cys Ser Leu His Pro Phe  
 15 20 25  
 caa gtc agc ttc cag cag ctg ggc tgg gat cac tgg atc att gct ccc 522  
 Gln Val Ser Phe Gln Gln Leu Gly Trp Asp His Trp Ile Ile Ala Pro  
 30 35 40 45  
 cat ctc tat acc cca aac tac tgt aag gga gta tgt cct cgg gta cta 570  
 His Leu Tyr Thr Pro Asn Tyr Cys Lys Gly Val Cys Pro Arg Val Leu  
 50 55 60  
 cac tat ggt ctc aat tct ccc aat cat gcc atc atc cag aac ctt gtc 618  
 His Tyr Gly Leu Asn Ser Pro Asn His Ala Ile Ile Gln Asn Leu Val

65					70					75						
agt	gag	ctg	gtg	gat	cag	aat	gtc	cct	cag	cct	tcc	tgt	gtc	cct	tat	666
Ser	Glu	Leu	Val	Asp	Gln	Asn	Val	Pro	Gln	Pro	Ser	Cys	Val	Pro	Tyr	
		80					85					90				
aag	tat	gtt	ccc	att	agc	atc	ctt	ctg	att	gag	gca	aat	ggg	agt	atc	714
Lys	Tyr	Val	Pro	Ile	Ser	Ile	Leu	Leu	Ile	Glu	Ala	Asn	Gly	Ser	Ile	
	95					100					105					
ttg	tac	aag	gag	tat	gag	ggt	atg	att	gcc	cag	tcc	tgc	aca	tgc	agg	762
Leu	Tyr	Lys	Glu	Tyr	Glu	Gly	Met	Ile	Ala	Gln	Ser	Cys	Thr	Cys	Arg	
110					115					120					125	
tgacggcaaaa	ggtgca															778

<210> 10  
 <211> 254  
 <212> PRT  
 <213> Ovis aries

<220>  
 <221> misc\_feature  
 <222> (376)..(387)  
 <223> furin protease sequence

<220>  
 <221> misc\_feature  
 <222> (479)..(479)  
 <223> position of Inverdale mutation

<220>  
 <221> misc\_feature  
 <222> (454)..(454)  
 <223> position of Hanna mutation

<220>  
 <221> misc\_feature  
 <222> (763)..(765)  
 <223> stop codon

<400> 10

Leu	His	Leu	Thr	His	Ser	His	Leu	Ser	Cys	His	Val	Glu	Pro	Trp	
				-125					-120					-115	

Val	Gln	Lys	Ser	Pro	Thr	Asn	His	Phe	Pro	Ser	Ser	Gly	Arg	Gly	
				-110					-105					-100	

Ser	Ser	Lys	Pro	Ser	Leu	Leu	Pro	Lys	Thr	Trp	Thr	Glu	Met	Asp	Ile
				-95					-90					-85	

Met	Glu	His	Val	Gly	Gln	Lys	Leu	Trp	Asn	His	Lys	Gly	Arg	Arg	Val
			-80					-75					-70		

Leu Arg Leu Arg Phe Val Cys Gln Gln Pro Arg Gly Ser Glu Val Leu  
 -65 -60 -55

Glu Phe Trp Trp His Gly Thr Ser Ser Leu Asp Thr Val Phe Leu Leu  
 -50 -45 -40

Leu Tyr Phe Asn Asp Thr Gln Ser Val Gln Lys Thr Lys Pro Leu Pro  
 -35 -30 -25 -20

Lys Gly Leu Lys Glu Phe Thr Glu Lys Asp Pro Ser Leu Leu Leu Arg  
 -15 -10 -5

Arg Ala Arg Gln Ala Gly Ser Ile Ala Ser Glu Val Pro Gly Pro Ser  
 -1 1 5 10

Arg Glu His Asp Gly Pro Glu Ser Asn Gln Cys Ser Leu His Pro Phe  
 15 20 25

Gln Val Ser Phe Gln Gln Leu Gly Trp Asp His Trp Ile Ile Ala Pro  
 30 35 40 45

His Leu Tyr Thr Pro Asn Tyr Cys Lys Gly Val Cys Pro Arg Val Leu  
 50 55 60

His Tyr Gly Leu Asn Ser Pro Asn His Ala Ile Ile Gln Asn Leu Val  
 65 70 75

Ser Glu Leu Val Asp Gln Asn Val Pro Gln Pro Ser Cys Val Pro Tyr  
 80 85 90

Lys Tyr Val Pro Ile Ser Ile Leu Leu Ile Glu Ala Asn Gly Ser Ile  
 95 100 105

Leu Tyr Lys Glu Tyr Glu Gly Met Ile Ala Gln Ser Cys Thr Cys Arg  
 110 115 120 125

<210> 11  
 <211> 16  
 <212> PRT  
 <213> Ovis aries

<400> 11

Ser Glu Val Pro Gly Pro Ser Arg Glu His Asp Gly Pro Glu Ser Cys  
 1 5 10 15

<210> 12  
 <211> 206  
 <212> DNA  
 <213> *Ovis aries*  
  
 <220>  
 <221> CDS  
 <222> (1)..(204)  
 <223> subset of Inverdale GDF9B nucleotide sequence around the mutation

<220>  
 <221> mutation  
 <222> (86)..(86)  
 <223> position of Inverdale mutation

<400> 12  
 ggc agt att gca tcg gaa gtt cct ggc ccc tcc agg gag cat gat ggg 48  
 Gly Ser Ile Ala Ser Glu Val Pro Gly Pro Ser Arg Glu His Asp Gly  
 1 5 10 15  
  
 cct gaa agt aac cag tgt tcc ctc cac cct ttt caa gac agc ttc cag 96  
 Pro Glu Ser Asn Gln Cys Ser Leu His Pro Phe Gln Asp Ser Phe Gln  
 20 25 30  
  
 cag ctg ggc tgg gat cac tgg atc att gct ccc cat ctc tat acc cca 144  
 Gln Leu Gly Trp Asp His Trp Ile Ile Ala Pro His Leu Tyr Thr Pro  
 35 40 45  
  
 aac tac tgt aag gga gta tgt cct cgg gta cta cac tat ggt ctc aat 192  
 Asn Tyr Cys Lys Gly Val Cys Pro Arg Val Leu His Tyr Gly Leu Asn  
 50 55 60  
  
 tct ccc aat cat gc 206  
 Ser Pro Asn His  
 65

<210> 13  
 <211> 68  
 <212> PRT  
 <213> *Ovis aries*

<400> 13  
 Gly Ser Ile Ala Ser Glu Val Pro Gly Pro Ser Arg Glu His Asp Gly  
 1 5 10 15  
  
 Pro Glu Ser Asn Gln Cys Ser Leu His Pro Phe Gln Asp Ser Phe Gln  
 20 25 30  
  
 Gln Leu Gly Trp Asp His Trp Ile Ile Ala Pro His Leu Tyr Thr Pro  
 35 40 45  
  
 Asn Tyr Cys Lys Gly Val Cys Pro Arg Val Leu His Tyr Gly Leu Asn

50

55

60

Ser Pro Asn His  
65

<210> 14  
<211> 206  
<212> DNA  
<213> Ovis aries

<220>  
<221> CDS  
<222> (1)..(60)  
<223> subset of Hanna GDF9B nucleotide sequence around the mutation

<220>  
<221> mutation  
<222> (61)..(61)  
<223> position of Hanna mutation

<400> 14  
ggc agt att gca tcg gaa gtt cct ggc ccc tcc agg gag cat gat ggg 48  
Gly Ser Ile Ala Ser Glu Val Pro Gly Pro Ser Arg Glu His Asp Gly  
1 5 10 15  
  
cct gaa agt aac tagtggtccc tccacccttt tcaagtcagc ttccagcagc 100  
Pro Glu Ser Asn  
20  
  
tgggctggga tcaactggatc attgctcccc atctctatac cccaaactac tgtaagggag 160  
tatgtcctcg ggtactacac tatggtctca attctcccaa tcatgc 206

<210> 15  
<211> 20  
<212> PRT  
<213> Ovis aries

<400> 15

Gly Ser Ile Ala Ser Glu Val Pro Gly Pro Ser Arg Glu His Asp Gly  
1 5 10 15

Pro Glu Ser Asn  
20

<210> 16  
<211> 1519  
<212> DNA  
<213> Trichosurus vulpecula

<220>

<221> Intron  
 <222> (1) .. (712)  
  
 <220>  
 <221> CDS  
 <222> (713) .. (1519)  
  
 <220>  
 <221> mat\_peptide  
 <222> (1178) .. ()  
  
 <220>  
 <221> exon  
 <222> (713) .. (1519)  
  
 <220>  
 <221> misc\_feature  
 <222> (1166) .. (1177)  
 <223> furin protease sequence

<400> 16  
 tttgtttatc tatgtcccaa atatTTTTTT ctccttttgg agcaaatgca aaggaaaggg 60  
 acttagctgg tgaagaatca gggtaggttg gaacaccac taaggaaagt gaaactatag 120  
 aaagagcact aggtctggac ctggggttaga atcctgtctt tgccacatct tagccgtgta 180  
 accttaggca agtggcttaa cttctctggg ctttcatttt atcttctgta aaatgagaca 240  
 tttccaactg tgggtctccat gcatttgcac tagctgttcc ctgtgcctgg aatgccctcc 300  
 ctcctttgtg tctcagaatc cttaatcttt cttctatctt cttttcttct cttcccctac 360  
 ttcccagtta ctactgctct ctccctctc aaatcacatt atgctgttct taccattcg 420  
 cacattatcg gattccaatc ctgctctctg cacggccccc ccccccggt agaacatgag 480  
 cttcttgaag gccaggcttg tttttcctct ctatgggtgcc tgacatatac aggagcttaa 540  
 taaacacttg ttgaccagat agtgtggagc tggctttgag ggggaagtga acctccccct 600  
 aattgggtcat ttatgatgcc aaggggagaag gcctaacaga actcttctct tggtcagggtg 660  
 ggttgggaag ctgacattct gttcttctta ccaccttcat tttctctgtg ca ggt 715  
 Gly  
 -155  
  
 ccc tgg tat gtg caa acc cta gac ttc cca ctt cgg cca aac cgt 760  
 Pro Trp Tyr Val Gln Thr Leu Asp Phe Pro Leu Arg Pro Asn Arg  
 -150 -145 -140  
  
 gac atg gac cat ctg gtg agg gcc gct gtt gct tac cgc cct cgc 805  
 Asp Met Asp His Leu Val Arg Ala Ala Val Ala Tyr Arg Pro Arg  
 -135 -130 -125  
  
 ctc cgc cta tct cac tcc cat ctt tcc tgc cat gtg gaa ccc tgg 850  
 Leu Arg Leu Ser His Ser His Leu Ser Cys His Val Glu Pro Trp  
 -120 -115 -110

gcc cac aag agc acc atc ctc ctg gga gga ggc tcc cca ggc ttt gct	898
Ala His Lys Ser Thr Ile Leu Leu Gly Gly Gly Ser Pro Gly Phe Ala	
-105 -100 -95	
ttg ccg gag gcc tgg gca gaa atg gat ctc acc aat tac att cag cag	946
Leu Pro Glu Ala Trp Ala Glu Met Asp Leu Thr Asn Tyr Ile Gln Gln	
-90 -85 -80	
caa gtt cag cct caa aag ggg agg aga gtc ctt cac atc caa gtc agg	994
Gln Val Gln Pro Gln Lys Gly Arg Arg Val Leu His Ile Gln Val Arg	
-75 -70 -65	
tgt cag cag caa gaa agg aca gag att ggc ctt ggg tgg agg cag gcc	1042
Cys Gln Gln Gln Glu Arg Thr Glu Ile Gly Leu Gly Trp Arg Gln Ala	
-60 -55 -50	
ttg gct act gac act gct ttc ctg gtt ctg tat ttc aac aat acc ttt	1090
Leu Ala Thr Asp Thr Ala Phe Leu Val Leu Tyr Phe Asn Asn Thr Phe	
-45 -40 -35 -30	
aaa agt gtg cca cga atg gag ctg cca gaa ctt ctg gtg ggg gac cct	1138
Lys Ser Val Pro Arg Met Glu Leu Pro Glu Leu Leu Val Gly Asp Pro	
-25 -20 -15	
gag gga gcc gat ctc ctt tcc ctg gcc cgg cga gtc cgt cag gtg ggc	1186
Glu Gly Ala Asp Leu Leu Ser Leu Ala Arg Arg Val Arg Gln Val Gly	
-10 -5 -1 1	
cct gta agg tct gaa gca cct ggc cag tca ctg gag cag aca cag tgt	1234
Pro Val Arg Ser Glu Ala Pro Gly Gln Ser Leu Glu Gln Thr Gln Cys	
5 10 15	
tct ctc cat cct ttc cag gtt agc ttc cac cag ctg ggc tgg gag aac	1282
Ser Leu His Pro Phe Gln Val Ser Phe His Gln Leu Gly Trp Glu Asn	
20 25 30 35	
tgg atc att gcc ccc cat ctg tac agc cca aac tac tgc aag ggg gcc	1330
Trp Ile Ile Ala Pro His Leu Tyr Ser Pro Asn Tyr Cys Lys Gly Ala	
40 45 50	
tgt cca cgg gtg cta cac tct ggc ctc cga tca ccc aac cat gcc atc	1378
Cys Pro Arg Val Leu His Ser Gly Leu Arg Ser Pro Asn His Ala Ile	
55 60 65	
att cag aac ctt atc aac gag ctg gtg gat aga agc atc ccc cga ccc	1426
Ile Gln Asn Leu Ile Asn Glu Leu Val Asp Arg Ser Ile Pro Arg Pro	
70 75 80	
tca tgc gtc cct tac aag tac atg ccc att agt gtc ctg ctg att gag	1474
Ser Cys Val Pro Tyr Lys Tyr Met Pro Ile Ser Val Leu Leu Ile Glu	
85 90 95	
gcc agt ggc agc atc ctg tac aaa gaa tat gag gac atg att gcc	1519
Ala Ser Gly Ser Ile Leu Tyr Lys Glu Tyr Glu Asp Met Ile Ala	
100 105 110	



<211> 269  
 <212> PRT  
 <213> Trichosurus vulpecula  
 <220>  
 <221> misc\_feature  
 <222> (1166)..(1177)  
 <223> furin protease sequence  
 <400> 17

Gly Pro Trp Tyr Val Gln Thr Leu Asp Phe Pro Leu Arg Pro Asn  
 -155 -150 -145

Arg Asp Met Asp His Leu Val Arg Ala Ala Val Ala Tyr Arg Pro  
 -140 -135 -130

Arg Leu Arg Leu Ser His Ser His Leu Ser Cys His Val Glu Pro  
 -125 -120 -115

Trp Ala His Lys Ser Thr Ile Leu Leu Gly Gly Gly Ser Pro Gly  
 -110 -105 -100

Phe Ala Leu Pro Glu Ala Trp Ala Glu Met Asp Leu Thr Asn Tyr Ile  
 -95 -90 -85 -80

Gln Gln Gln Val Gln Pro Gln Lys Gly Arg Arg Val Leu His Ile Gln  
 -75 -70 -65

Val Arg Cys Gln Gln Gln Glu Arg Thr Glu Ile Gly Leu Gly Trp Arg  
 -60 -55 -50

Gln Ala Leu Ala Thr Asp Thr Ala Phe Leu Val Leu Tyr Phe Asn Asn  
 -45 -40 -35

Thr Phe Lys Ser Val Pro Arg Met Glu Leu Pro Glu Leu Leu Val Gly  
 -30 -25 -20

Asp Pro Glu Gly Ala Asp Leu Leu Ser Leu Ala Arg Arg Val Arg Gln  
 -15 -10 -5 -1 1

Val Gly Pro Val Arg Ser Glu Ala Pro Gly Gln Ser Leu Glu Gln Thr  
 5 10 15

Gln Cys Ser Leu His Pro Phe Gln Val Ser Phe His Gln Leu Gly Trp  
 20 25 30

Glu Asn Trp Ile Ile Ala Pro His Leu Tyr Ser Pro Asn Tyr Cys Lys  
35 40 45

Gly Ala Cys Pro Arg Val Leu His Ser Gly Leu Arg Ser Pro Asn His  
50 55 60 65

Ala Ile Ile Gln Asn Leu Ile Asn Glu Leu Val Asp Arg Ser Ile Pro  
70 75 80

Arg Pro Ser Cys Val Pro Tyr Lys Tyr Met Pro Ile Ser Val Leu Leu  
85 90 95

Ile Glu Ala Ser Gly Ser Ile Leu Tyr Lys Glu Tyr Glu Asp Met Ile  
100 105 110

Ala

**THIS PAGE BLANK (USPTO)**

This Page is inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

## BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLORED OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REPERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images problems checked, please do not report the problems to the IFW Image Problem Mailbox**

**THIS PAGE BLANK (USPTO)**